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ABSTRACT 
Endemic Burkitt lymphoma (eBL) is the most common pediatric cancer in 
malaria-endemic equatorial Africa and nearly always contains Epstein-Barr virus 
(EBV), unlike sporadic Burkitt Lymphoma (sBL) that occurs with a lower incidence 
in developed countries. Despite this increased burden the study of eBL has lagged. 
Additionally, while EBV was isolated from an African Burkitt lymphoma tumor 50 
years ago, however, the impact of viral variation in oncogenesis is just beginning to 
be fully explored. In my thesis research, I focused on investigating molecular 
genetics of the endemic form of this lymphoma with a particular emphasis on the 
role of the virus and its variation in pathogenesis using novel sequencing and 
bioinformatic strategies. 
First, we sought to understand pathogenesis by investigating transcriptomes 
using RNA sequencing (RNAseq) from 30 primary eBL tumors and compared to sBL 
tumors. BL tumor samples were prospectively obtained from 2009 until 2012 in 
Kenya. Within eBL tumors, minimal expression differences were found based on 
anatomical presentation site, in-hospital survival rates, and EBV genome type; 
suggesting that eBL tumors are homogeneous without marked subtypes. The 
outstanding difference detected using surrogate variable analysis was the 
significantly decreased expression of key genes in the immunoproteasome complex 
in eBL tumors carrying type 2 EBV compared to type 1 EBV. Secondly, in 
comparison to previously published pediatric sBL specimens, the majority of the 
7 
expression and pathway differences was related to the PTEN/PI3K/mTOR signaling 
pathway and was correlated most strongly with EBV status rather than the 
geographic designation. Moreover, the common mutations were observed 
significantly less frequently in eBL tumors harboring EBV type 1, with mutation 
frequencies similar between tumors with EBV type 2 and without EBV. In addition 
to the previously reported genes, we identified a set of new genes mutated in BL. 
Overall, these suggested that EBV, particularly EBV type 1, supports BL 
oncogenesis alleviating the need for certain driver mutations in the human genome. 
Second, we sought to comprehensively define sequence variations of EBV 
across the viral genome in eBL tumor cells and normal infections, and correlate 
variations with clinical phenotypes and disease risk. We investigated the whole 
genome sequence of EBV from primary tumors (N=41) and plasma from eBL 
patients (N=21) as well as EBV in the blood of healthy children (N=29) within the 
same malaria endemic region. We conducted a genome wide association analysis 
study with viral genomes of healthy kids and BL kids. Furthermore, we found that 
the frequencies of EBV types among healthy kids were at equal levels while they 
were skewed in favor of type 1 (70%) among eBL kids. To pinpoint the fundamental 
divergence between viral genome subtypes, type 1 and type 2, we constructed 
phylogenetic trees comparing to all public EBV genomes. The pattern of variation 
defined the substructures correlated with the subtypes. This investigation not only 
deciphers the puzzling pathogenic differences between subtypes but also helps to 
understand how these two EBV types persist in the population at the same time. 
8 
Overall, this research provides insight into the molecular underpinning of 
eBL and the role of EBV. It further provides the groundwork and means to unravel 
the complexity of EBV population structure and provide insight into the viral 
variation that may influence oncogenesis and outcomes in eBL and other EBV-
associated diseases. In addition, genomic and mutational analyses of Burkitt 
lymphoma tumors identify key differences based on viral content and clinical 
outcomes suggesting new avenues for the development of prognostic molecular 
biomarkers and therapeutic interventions. 
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1.1 Burkitt Lymphoma 
 
Burkitt lymphoma (BL) is a monoclonal B-cell non-Hodgkin's lymphoma  
(Burkitt and Denis 1961). It is composed of monomorphic, medium sized cells with 
basophilic cytoplasm and one of the highest proliferation rates known for human 
tumors  (Armitage and Weisenburger 1998). Its histological appearance is “sky” like 
with a background of homogeneous tumor cells punctuated by “stars” consisting of 
macrophages at apoptotic foci (see Figure 1.1). BL is characterized by 
overexpression of the MYC gene, in the vast majority of cases, due to a chromosomal 
translocation  (Hecht and Aster 2000; I. T. Magrath 1991). BL tumor cells usually 
express GC centroblast markers such as CD10, CD77, and BCL6. Besides, BL 
tumors are positive for B cell surface markers CD19, CD20 and CD22 and negative 
for BCL2  (Ferry 2006a). 
The World Health Organization recognizes three clinical subtypes of BL: 
endemic BL (eBL), sporadic BL (sBL), and immunodeficiency-related BL (idBL). 
eBL has an annual incidence of 5-15 cases in 100,000 children in areas experiencing 
perennial Plasmodium falciparum transmission. Both EBV infection and 
holoendemic P. falciparum are thought to be etiologically linked to the development 
of this B cell cancer (reviewed in Moormann and Bailey 2016). In contrast to eBL, 
pediatric sBL is found at a 10-fold lower incidence in developed countries where 
malaria is not endemic and only associated with EBV in around 10% to 20% of 
cases. Pediatric sBL tends to afflict a higher proportion of males and adolescents 
18 
and present in the abdomen often with disseminated disease  (Satou et al. 2015). 
sBL incidence has a bimodal age distribution with peaks in children and older 
adults suggesting different etiologies. Adults BL tends to have higher rates of EBV 
positivity, nodal presentation, along with poorer outcome, and often more variable 
pathologic features leading to designations of plasmacytoid or atypical BL  (Ferry 
2006a). These differences within sBL have raised the suggestion that adult sBL 
should be considered a separate entity  (Boerma et al. 2004a) as well as EBV-
positive and EBV-negative tumors  (B.-J. Chen et al. 2016a). 
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Figure 1.1. Histological appearance of Burkitt Lymphoma under microscope 
(provided by Dr. Sava Solomon Syanda and Dr. Juliana Otieno, JOORTH, Kenya)  
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eBL commonly presents in the jaw or facial bones as well as other extranodal 
sites such as the GI tract, kidneys, and breasts. However, jaw and abdominal 
tumors are the most common anatomical sites of presentation (50-80% of cases) in 
pediatric eBL  (I. T. Magrath 1991; Buckle et al. 2016c). It has been suggested that 
there are different epidemiological patterns associated with the clinical 
presentation of BL. Endemic BL shows distinctive presentation in either the jaw or 
the abdomen  (Mwanda 2004); among Kenyan children within our larger BL cohort, 
the tumor presentation sites are 43% jaw and 50% abdomen (see Figure 1.2)  
(Buckle et al. 2016a). Children with jaw tumors tend to be younger and mostly 
males, while abdominal BL tumors present more common among older children and 
are equally distributed between males and females  (Ogwang et al. 2008; Asito et al. 
2010a). Differences are also seen in childhood with sporadic BL (that is only 
associated with EBV in 30-40% of cases) where jaw involvement is rare in favor of 
abdominal and nodal masses  (Mbulaiteye et al. 2009). Despite the observed clinical 
and pathologic differences, most studies over the years view eBL as a single clinical 
entity and attribute survival differences to delayed presentation and variability in 
treatments  (Buckle et al. 2016c). Given the epidemiological differences associated 
with the site of tumor presentation that is incorporated into staging disease, there 
may be molecular differences underlying eBL tumor tropism that have not been 
fully elucidated. Clinical features of eBL and response to conventional 
chemotherapy have not been examined with regards to expression or mutational 
profile of the tumor. Also, during the study period between 2003 and 2011, 22% of 
21 
the admitted patients died in-hospital, and 78% completed the course of 
chemotherapy treatment  (Buckle et al. 2016a). In this respect, there was a 
dramatic difference between the survival rates with 63% of patients with jaw 
tumors surviving compared to 33% for abdominal tumors. Attempts to associate 
antibody titers with tumor presentation site and prognosis has shown that anti-Zta 
IgG levels were elevated in eBL patients with abdominal tumors compared to 
patients with jaw tumors  (Asito et al. 2010b). However, high throughput expression 
profiling and comparative assays applied here better address the question of 
distinct molecular features unique to tumor localization or survival outcome. 
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Figure 1.2. eBL patient children with a jaw presentation (on the left) and an 
abdominal presentation (on the right). Photos have been approved by written 
consent from the parents to be used for research and educational presentation 
(JOOTRH, Kisumu, Kenya). 
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Burkitt lymphoma is the first human cancer for which a translocation 
associated with an oncogene was identified. Virtually all BL cases share the 
presence of one of the three reciprocal translocations involving the MYC locus on 
chromosome 8 and either immunoglobulin heavy (IgH) chain locus (chromosome 14) 
or one of the light chain (kappa, lambda) loci on chromosome 2 or chromosome 22  
(I. Magrath 1990). The most common one is the translocation between chromosome 
8 and chromosome 14, known as t (8;14). Determining the chromosomal breakpoint 
locations is important because it may assist to identify in which stage of the B cell 
differentiation the translocation has occurred. It has been found that the 
distribution of breakpoint locations and the type of structural alterations differ eBL 
and sBL tumors  (Pelicci et al. 1986). The breakpoints on chromosome 8 localized in 
the far upstream region of the MYC gene in eBLs, and in contrast, within the first 
exon or first intron of the MYC locus in sBLs. The breakpoints on chromosome 14 
accumulated differently in eBLs as they mostly appeared the Ig joining region as 
opposed to sBLs which carried breakpoints in the switch regions. In neither case, 
the coding sequence is disrupted. However, the translocation of MYC locus causes 
deregulated expression due to being in close proximity of active Ig promoters. Thus, 
deregulated expression results in accelerated cell proliferation (Boxer and Dang, 
2001).  
Studies investigating the potential of using gene expression profiling for 
accurate diagnosis of Burkitt Lymphoma resulted in molecularly defining the BL 
(mBL, molecular BL, as named in the studies)  (Hummel et al. 2006; Dave et al. 
24 
2006). By utilizing the gene expression profiles of validated BL tumors as a 
classifier, they identified and correctly diagnosed new tumors. This helped to 
distinguish BL from other aggressive B-cell lymphomas (non-mBL) such as diffuse 
large B-cell lymphoma. The most important feature of the classifier has reported as 
the level of MYC gene expression, which is the result of the translocation, to 
separate BL from other lymphomas. Following gene expression studies have also 
argued that the three subtypes of BL had distinct pathogenic mechanisms and 
demonstrated that eBL and idBL had similar gene expression profiles, whereas sBL 
was relatively more distinct  (Piccaluga et al. 2011a).  
MYC oncogene deregulation and ectopic expression by chromosomal 
translocations is the key molecular driver and hallmark of BL. Even though 
deregulated expression and subsequent mutations of MYC gene severely alter the 
DNA binding efficiency of this transcription factor, these do not appear to be 
sufficient for tumorigenesis  (Janz, Potter, and Rabkin 2003). The search for 
additional driver mutations in sBL has yielded several candidate tumor suppressors 
and oncogenes  (Schmitz et al. 2012a; Richter et al. 2012; C. Love et al. 2012). 
However, eBL primary tumor biopsies have not been studied at a genome-wide level 
until recently with limited numbers of cases  (Abate et al. 2015a). The most common 
driver mutations in coding regions appear to occur in the transcription factor TCF3 
(E2A) and its inhibitor ID3. Cell cycle regulator gene CCND3 which encodes for 
cyclin D3 is another gene frequently mutated especially in sBL cases.  
25 
Aside from geography differences in incidence, eBL has a polymicrobial 
etiology involving two ubiquitous pathogens, Epstein Barr Virus (EBV) and 
Plasmodium falciparum  (Morrow 1985; Rochford, Cannon, and Moormann 2005). 
EBV asymptomatically infects more than 90% of adult population world-wide which 
leads to lifelong persistence (Thorley-Lawson and Gross, 2004). The greatest 
difference in EBV prevalence in BL tumor classifications is seen between endemic 
(95%) and sporadic pediatric BL (10%) tumors. EBV positivity is intermediate in id-
BL  (Ferry 2006b; Satou et al. 2015) and increases with age in sporadic adult cases 
(30-50%)  (Satou et al. 2015), which is expected given that increased age correlates 
with higher chance of EBV exposure. Unlike other lymphomas such as Hodgkin's  
(Jarrett et al. 2005) and DLBCL  (Park et al. 2007), EBV has not been associated 
with outcome  (Satou et al. 2015). It does appear that EBV-positive tumors may 
share a similar B cell origin compared to EBV-negative tumors regardless of 
geographic origin  (Navari et al. 2015). Adult sBL tends to have higher rates of EBV 
positivity, nodal presentation, along with poorer outcome, and often more variable 
pathologic features leading to designations of plasmacytoid or atypical-BL  (Ferry 
2006b). These differences within sBL have raised the suggestion that adult sBL 
should be considered as a separate entity  (Boerma et al. 2004b) as EBV-positive 
and EBV-negative tumors are defined separately  (B.-J. Chen et al. 2016b). 
Supporting this, a causal relationship between EBV positivity and age onset has 
been reported in a study conducted in southeastern Brazil  (Hassan et al. 2008).  
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P. falciparum is a protozoan parasite causing malaria in >200 million people 
and resulting in >400,000 deaths annually (WHO 2016). Both early onset of 
primary EBV infection and high malaria transmission play a significant role in 
increased risk of BL in Africa. In locations where malaria transmission is stable and 
intense (i.e. holoendemic malaria), the eBL incidence is high, in contrast to a 
significantly lower eBL incidence in hypoendemic areas where malaria transmission 
is unstable and sporadic  (Rainey 2005). The precise mechanisms malaria pathogen 
which may play in the development of this malignancy remains to be elucidated. 
Two possible mechanisms have been proposed; the first is by suppression of T cell 
immunity or by activation and expansion of B cells. It has been reported that 
children diagnosed with eBL were defective for EBNA1 specific IFN-gamma T cell 
responses  (Moormann et al. 2009a). Besides, malaria parasites are powerful 
polyclonal stimulators of B cell system  (Donati et al. 2004). Thus, exposure to a 
large number of several Plasmodium falciparum antigens during multiple 
infections can cause EBV to reactivate from memory B cells  (Chêne et al. 2007). 
This leads to a higher viral load and increased EBV-infected B cells  (Donati et al. 
2006). It has been hypothesized that chronic and persistent malaria infection 
exploits immune regulatory mechanisms that influence EBV control, the high EBV 
viremia would, therefore, increase the likelihood of B cell transformation by latent 
EBV, initiating eBL carcinogenesis  (Torgbor et al. 2014a). Since high EBV viremia 
is a characteristic in malaria holoendemic areas and thought to be crucial in the 
development of eBL, ineffective immune surveillance for the virus or nascent tumor 
27 
by innate immune responses could increase a child’s risk of developing eBL in a 
malaria holoendemic environment  (Wilmore et al. 2015). Activation-induced 
cytidine deaminase (AID) is responsible for immunoglobulin hypermutation and 
class-switch recombination during B cell activation  (Krieg 2000; Peng 2005; 
Ruprecht and Lanzavecchia 2006). Inducing AID activation is thought to increase 
the likelihood of MYC translocation, which is the hallmark genetic aberration of 
eBL tumors  (Weiner 2009; Robbiani et al. 2015).  
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1.2 Epstein Barr Virus 
Virus infections are responsible for ~15% of human cancer deaths  
(McLaughlin-Drubin and Münger 2009). EBV is one of these and known to be 
responsible for driving the proliferation and survival of infected B cells by 
expressing multiple viral oncogenes (Young and Murray 2003). However, EBV 
resides in resting memory B cell compartment of healthy individuals, and they 
typically carry 1-50 EBV-positive cells out of 1,000,000 B lymphocytes  (Khan et al. 
1996). Accumulated evidence shows that the virus does not require cell 
transformation or tumorigenesis for its replication and can persist without them. 
These are most likely consequences of complex molecular virus-host interactions. 
On the contrary, some of the viral genes, rather oncogenes, are required to be 
ubiquitously expressed for tumor cell survival. Even though EBV's role is not 
entirely understood, it is possible that EBV might contribute to the pathogenesis of 
BL by a “Hit and Run” mechanism. Supporting this, it has been demonstrated that 
EBV may not be associated with relapses following treatment  (Xue et al. 2002).  
Following the entrance to the cell, the viral genome is delivered to nucleus 
through an unknown mechanism. After delivery, linear genomes become 
circularized to protect itself from nucleases and is maintained in an episomal state, 
although there are rare reports of viral genomes integrated into the host genome. 
EBV does not have an RNA polymerase encoded by itself; thus, it uses cellular 
transcriptional machinery, RNA pol II. Early viral transcriptional activity is chaotic 
and not regulated well until the latency is established. Once the latency state is 
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reached, virus controls most of the activity and only allows a limited number of 
transcriptions. In BL tumor cells, latency I is the predominant state which involves 
the expression of EBNA1 as the sole protein coding genes in addition to non-coding 
EBERs, BART region transcripts, and microRNAs  (Rowe et al. 1987; Kelly, Bell, 
and Rickinson 2002a). On the other hand, virus shows almost no expression activity 
(except EBERs) in PBMCs’ of healthy carriers, also known as latency 0 state. In 
latency II state, viral genes LMP genes are also expressed in addition to latency I 
genes (Price and Luftig, 2015). Expression profile of virus in cultured BL cells or 
LCLs in latency III have slight differences as opposed to ones in primary BL cells. 
This difference mainly originates from the different usage of promoter site Cp (Wp), 
mostly in LCLs, and Qp in BLs.  
The infecting EBV genome in eBL patients can be either of two divergent 
strains, type 1 or type 2, and comparative genomic studies have demonstrated type-
specific divergence  (Cohen et al. 1989a; Rowe et al. 1989; Dambaugh et al. 1984a). 
While type 1 EBV is found globally, type 2 is more commonly found in Africa than 
other parts of the world  (Zimber et al. 1986). Although it has been reported that the 
transformation efficiency of EBV type 1 is higher compared to type 2 in 
lymphoblastoid cell line establishments  (Rickinson, Young, and Rowe 1987a), both 
strains are frequently found in African eBL cases and are prevalent within healthy 
populations in sub-Saharan Africa  (Rowe et al. 1989; L. S. Young et al. 1987b). 
However, the expression and mutational profiles of EBV type 1 and type 2 within 
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primary eBL tumors have not been compared and contrasted to determine if viral 
variation influences tumorigenesis. 
Molecularly, type 1 and type 2 are represented by major latent genes, the 
coding sequences for EBNA2 and EBNA3-A/B/C genes  (Dambaugh et al. 1984b). In 
the efficiency difference between the two subtypes in making lymphoblastoid cell 
lines, EBNA2 has been found to be the key determinant (Cohen et al. 1989b). 
Recently supporting the role of EBNA2, it is reported to be the primary factor 
differentiating the transformation efficiencies of two types (Lucchesi et al. 2008). 
Both types also differ in several molecular properties such as their entrance to lytic 
cycle  (Buck et al. 1999) and ability to infect T cells  (Coleman et al. 2015). 
Following their discovery about the transformation efficiency differences between 
subtypes, Alan Rickinson and his colleagues measured the population frequency of 
type 2 infections as ~23% among normal individuals in Kenya and New Guinea by 
generating spontaneous LCLs  (L. S. Young et al. 1987a). Originating from these, it 
is widely known that type 1 EBV is the dominant type all around the world, type 2 
is more commonly found in Africa. In contrary, a group of healthy adults in the USA 
was screened for EBV types using PCR and the study found almost equal levels of 
type 1 (41%, N=14) and type 2 (50%, N=17) in addition to individuals carrying both 
(9%, N=3)  (Sixbey et al. 1989). 
Starting from the 1990s, it has often been hypothesized that EBV genomic 
variations may contribute to pathogenesis. These studies were initially oriented 
around subtype-specific genomic regions and pathologic differences between 
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diseases (Tzellos and Farrell, 2012). One of the focuses especially was on 
immunocompromised patients since the early observations showed increased type 2 
infection rates among such individuals. A study conducted in Australia reported 
that 26 LCLs from HIV infected subjects carried 69% type 1, 19% type 2, and 12% 
both types  (Sculley et al. 1990).  
A central challenge is that that establishing LCLs for investigating viral type 
frequencies is inherently biased given type 1 EBV’s better transformation 
properties. Alternatively, PCR-based methods generated relatively better and 
reliable results. Another follow-up study with PCR instead of LCL generation 
showed that 24% (N=15) of the HIV-positive patients were infected with type 1 
while 27% (N=17) were with type 2 and 39% (N=24) were with both types. In 
addition, 39% of the cardiac transplant patients were infected with type 1 while 
33% were with type 2 and 28% were with both types  (Kyaw et al. 1992). The skew 
in the typing towards type 1 EBV when LCL method is used as opposed to PCR has 
been demonstrated. Boyle et al. screened 30 Hodgkin’s Disease patients for EBV 
and found that 7 of these had type 1 and 2 of them had type 2. Interestingly, two 
patients with type 2 EBV immunocompromised as they were infected with HIV 
suggesting that type 2 EBV is important pathogen for immunocompromised 
individuals  (Boyle et al. 1993). Supporting this, immunocompromised HIV-positive 
homosexuals had slightly higher type 2 EBV infection rates compared to other 
healthy Caucasian individuals in another work  (Yao et al. 1998a). On the other 
hand, among the Taiwanese NPC (Nasopharyngeal Carcinoma), head and neck 
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carcinoma, and saliva from healthy individuals, type 1 was the predominant type  
(Shu et al. 1992). Another study conducted with Brazilian BL cases found the 
majority of the tumors as type 1 EBV-carrying (93%, N=13) and 80% of the virus 
had a 30 bp deletion in their LMP-1 gene  (W. G. Chen et al. 1996). A study 
conducted among healthy individuals from Japan using saliva and throat washings 
showed that the majority of carriers were infected with type 1 (90%)  (Ikuta et al. 
2000). Multiple cancer types predominantly carry only type 1  (Peh, Kim, and 
Poppema 2002). No associations have been found between NPC cases and various 
genotypes of the virus, including subtypes type 1 and type 2, relative to healthy 
population  (Cui et al. 2011). 
Overall these early attempts to measure subtype frequencies were sporadic 
and involved small study sizes. In addition to concerns regarding the limited 
samples, researchers have concluded that the generation of LCLs creates a 
bottleneck for types and skews the results. Alternative methods such as PCR-based 
assays provided relatively better estimations, however; patient/donor selection 
criteria relying on viral load levels of individuals also created unbalanced/non-
random sampling especially towards immunocompromised people. In other words, 
picking only patients with high viral loads is a non-randomized sampling of 
populations. 
The desire to determine type frequencies globally lead scientists to conduct 
many studies around the world. In one of these attempts from Argentina, type 1 
was found in 76% of healthy carriers while type 2 was in 15% and 7% of individuals 
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were co-infected with both types  (Correa et al. 2004). In Mexico, 33% carried type 1, 
57% type 2, and 10% was a mixed infection  (Palma et al. 2013). The predominant 
type was found to be type 1 with 98% frequency in Australia  (Lay et al. 2012). 
These various studies to understand the viral subtype prevalence and attempts to 
associate with diseases have yet to form a consensus profile as reviewed in Neves et 
al.  (Neves et al. 2017). However, the prevalence of type 2 infections might still be 
associated with disturbance of immune system (AIDS patients) or chronic immune 
activation as we observe individuals in malaria-endemic regions. As a summary, the 
claim that the most of the populations carry type 1 more frequently than type 2 is a 
flawed statement because such generalization to population levels relies on studies 
with mostly disease associated cases not all types of individuals including healthy 
people. 
Regarding the mixed type infections, a study conducted by Barlee et al. found 
no association between mixed (superinfection) or type 2 EBV infection and acquired 
immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma in a study 
using type specific nested PCR on PBMCs of patients  (van Baarle et al. 1999). The 
study concludes that detecting virus type directly from PBMCs is more sensitive 
than a cultured virus grown with sLCLs from same PBMCs. Secondly, HIV-infected 
individuals have high type 2 EBV infection prevalence, however; this does not 
increase the risk for developing AIDS-related NHL. Also, contrary to previous 
findings, they found no correlation between type 2 infection and immune system 
failure. In conclusion, these suggested that type 2 infection was only correlated with 
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HIV infection but not with immunodeficiency in agreement with an earlier work 
using PCR assays reporting that the 50% of the EBV-positive HIV-associated non-
Hodgkin lymphoma patients carried type 2  (Boyle et al. 1991). Similarly, another 
study found that HIV-positive patients carry multiple strains both type 1 and type 2  
(Yao, Tierney, Croom-Carter, Dukers, et al. 1996). Interestingly, following results 
have been reported with slightly higher mixed infection rates by Sculley et al as 
35%, 27%, and 21%, type 1, type 2, and both, respectively  (Apolloni and Sculley 
1994) and as 69%, 19%, and 12%, type 1, type 2, and both, respectively  (Sculley et 
al. 1990). 
Such first generation PCR-based frequency measurements are also not 
reliable regarding detecting mixed infection since they can simply return false 
positive results because of their lack of quantitative properties. The mixed type 
cases were prone to false results and probably overestimated when overly sensitive 
PCR was used. Thus, these early studies trying to estimate mixed infection rates 
should be evaluated cautiously. To determine superinfection cases or accurately 
assess the level of mixed infections, quantitative PCR (qPCR) assays with 
multiplexed reactions are required. Specifically for EBV subtypes, Gatto et al. 
developed such test which can be utilized for better estimation of mixed infections  
(Gatto et al. 2011). Alternatively, a recently developed method using quantitative 
sequencing called molecular inversion probes (MIPs) can be utilized with unique 
molecular identifiers. This targeted capture PCR allows correcting for sequencing 
errors and properly quantitating initial levels of DNA mixtures in clinical samples. 
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The viral genome variant association studies involving NPC outnumbers any 
other diseases. Early attempts investigating sequence variations emerged with 
restriction site polymorphisms (aka RFLP) and majorly focused on BamHI and XhoI 
variants. RFLP studies showed that variants of BamHI region are more frequent in 
Asian strain than Europe, N America, and Africa  (Khanim et al. 1996; Cho and Lee 
2000). This was the first associated with NPC, but it was in fact just a geographic 
variant. Similarly, major LMP1 variants were named after countries that they were 
first found in (Chinese, Alaskan, North Carolina, etc.). LMP1 gene codon deletion 
has been associated with NPC  (Cheung et al. 1998) in addition to the different 
subgroups of LMP1 sequences  (Tiwawech et al. 2008). These studies involved 
amplicon sequencing with a low satisfactory amplification rate. Loss of XhoI site 
and 30bp deletion at the C-terminal have been associated with Nasopharyngeal 
carcinoma or increased tumorigenicity  (Hu et al. 1993, 1991; Jeng et al. 1994). An 
SNV in the RPMS1 coding region has been found to be strongly associated with risk 
of NPC  (Feng et al. 2015). Sequence analysis of immediate early gene BRLF1, Rta, 
demonstrated significantly different sequence subgroups among various patient and 
control groups  (Jia et al. 2010). Sequence variations in EBNA1 are important for 
recognition of infected cells by CD8+ T-cells because it is the single protein coding 
gene in latency state in all EBV-associated malignancies. Thus, it is also targeted 
by researchers to associate its variations with MHC class I types  (Bell et al. 2008). 
Viral subtype and RFLP polymorphism association study on EBVaGC  (Corvalan et 
al. 2006). EBNA1 and LMP1 variant association case-control study using amplicon 
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sequencing found no association between the variants and multiple sclerosis  
(Simon et al. 2011). Sandvej et al. and several others found these variants, however, 
in viral genomes of healthy carriers and patients with non-EBV associated diseases  
(Sandvej et al. 1997). Despite these various attempts to determine virulent strains 
and associate these with certain disease types, there is not a clear consensus on 
results most likely due to limited access to clinical specimens and technical 
challenges. Especially, such association studies regarding BL are greatly lacking. 
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1.3 Motivation and Research Goals 
Further investigations into the mechanisms EBV-host interactions is 
warranted to increase understanding of EBV infection and body defense 
mechanisms that may facilitate the development of novel strategies for controlling 
EBV infection and reducing eBL carcinogenesis. Thus, a comprehensive study 
design that will compare gene expression patterns and genomic variations of biopsy 
samples from eBL and sBL using next-generation sequencing can provide a high-
resolution understanding of this divergence in the context of EBV infection.  
In this research, my overall goal was to investigate genomic and 
transcriptomic alterations as well as the known cofactors of tumor initiation and 
progression. I utilized the next generation sequencing in conjunction with 
computational techniques to address two specific aims. I proposed: (1) to 
determine the genomic and transcriptomic differences between endemic 
Burkitt lymphoma and sporadic Burkitt lymphoma and correlate 
transcriptomes of endemic Burkitt lymphoma with clinical/molecular 
phenotypes; (2) to determine if the EBV genomic variations correlate with 
geography (confounded by malaria endemicity) and/or eBL diagnosis 
given the same malaria exposure using a case-control study design. Results 
from this research provided new insight into genetic alterations that contribute to 
eBL etiology and helped to understand roles of pathogens in the disease 
development.  
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The hypothesis was that eBL differs from sBL regarding gene expression 
profiles and mutated gene distributions. Regarding the genomic and transcriptomic 
differences between endemic BL and sporadic BL, I used high-throughput 
sequencing to spontaneously measure the expression levels of multiple samples and 
determine whether there were genes differentially expressed and whether their 
expression pattern correlated with BL subtypes. I determined the mutational profile 
and mutated gene rate differences between the BL subtypes. I also investigated the 
effect of EBV’s presence and type on these mutational profile differences by 
conducting a comparative analysis. In the second part of my research, I worked on 
the topic of viral genomes in tumors because I wanted to find out possible roles of 
sequence variations in pathogenesis through molecular interactions so that it can 
help to develop better therapeutic vaccines against viral infections.  
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Chapter II. Endemic Burkitt Lymphoma  
Expression and Mutations 
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2.1 Summary 
 
Endemic Burkitt lymphoma (eBL) is the most common pediatric cancer in 
malaria-endemic equatorial Africa and nearly always contains Epstein-Barr virus 
(EBV), unlike sporadic Burkitt Lymphoma (sBL) that occurs with a lower incidence 
in developed countries. Given these differences and the variable clinical 
presentation and outcomes, we sought to further understand pathogenesis by 
investigating transcriptomes using RNA sequencing (RNAseq) from multiple 
primary eBL tumors compared to sBL tumors. Here we investigate the 
transcriptome and mutational profiles of 28 eBL and two sBL primary tumors by 
deep sequencing and unlike previous studies; we correlated our findings with 
clinical outcomes. We also explored the viral gene expression activity in EBV 
positive BL tumors comparing and contrasting type 1 and type 2 virus. 
 
2.2 Methods 
To better compare BL subtypes, we also analyzed published RNAseq dataset 
of sBLs and cell lines  (Schmitz et al. 2012b). The sequences in the fastq format 
were downloaded through the NCBI (SRP009316) for 28 sBL primary tumors and 
13 long term BL cultures derived from sporadic and endemic cases. In addition, we 
also analyzed 89 mRNA sequencing from lymphoblastoid cell lines (LCLs) from 
healthy individuals involved in the 1000 genome project (Yoruba, YRI) 
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(ERP001942), which we used to eliminate variant calls likely due to transcript 
assembly, mapping artifacts or RNA editing. 
 
2.2.1 Sequencing Library Preparation 
Briefly, starting with 1-5ug total RNA, we prepared strand-specific RNAseq 
libraries following the protocol from Zhang et al.  (Zhang et al. 2012) combined with 
mRNA enrichment with oligo-dT using Dynabeads mRNA purification kit (Life 
Technologies) (see Chapter III for details). Final library qualities were confirmed 
with Bioanalyzer High Sensitivity DNA kit (Agilent) and sequenced with paired end 
read (2x100bp) using multiple lanes of Illumina HiSeq 2000 (Illumina Inc., San 
Diego, CA, USA). Data can be accessed at dbGAP with accession number 
(phs001282.v1.p1). 
 
2.2.2 Differential Gene Expression Analysis 
After quality assessment and preprocessing the raw sequencing reads, we 
aligned read pairs to a transcriptome index built by RSEM  (Li, Bo, and Dewey 
2011a) using Gencode v19 protein coding transcript annotations and hg19 genomic 
sequence. For EBV genes, we used GenBank gene annotations from both the type 1 
and type 2 reference genomes (NC_007605 and NC_009334, respectively). To 
perform differential gene expression test, we used DESeq2 (M. I. Love, Huber, and 
Anders 2014a) in R computing environment. In order to be able to account for the 
batch variables and unknown factors while testing for the differential expression, 
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we estimated the number of latent factors for every comparison separately using 
svaseq (Leek 2014a) while preserving the variation of interest. We then 
incorporated these surrogate variables into the testing model for DESeq2. 
 
2.2.3 Gene Set Enrichment Analysis 
We performed a standard gene set enrichment analysis (GSEA) using the 
GSEA module implemented by Broad Institute, Cambridge, MA (Subramanian et 
al. 2005). GSEA was performed on normalized expression data and data after 
surrogate variable analysis. For a ranking metric, we used the signal to noise value 
of each gene and performed a permutation test for FDR by permuting sample 
phenotypes. The analysis included standard gene sets of hallmark and oncogenic 
signatures as well as the curated C2 gene sets from the Molecular Signatures 
Database (v5.0 MSigDB) (Liberzon et al. 2011). 
 
 
2.2.4 Single Nucleotide Variation Detection 
We mapped sequencing reads to human reference genome hg19 using the 
spliced aligner STAR (Dobin et al. 2013a) after quality trimming and removing the 
PCR duplicate reads. We followed the standard work flow by GATK (McKenna et al. 
2010a) for calling variation within RNAseq data using the HaplotypeCaller module 
with additional stringency requirements (see Chapter III for details). Variants 
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observed in dbSNP v146 and low-quality calls were excluded. We limited variant 
calling to translated sequences of protein coding genes in GenCode annotation v19. 
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2.3 Results 
2.3.1 Case Information and Sequencing Summary 
To survey the transcriptome of eBL, we sequenced 28 primary histologically-
confirmed tumor FNA biopsies collected from Kenyan children with median age 8.2 
years old (Table 2.1). We also sequenced two fresh frozen sBL tumors from 
diagnostic biopsies at the University of Massachusetts Medical School (UMMS). For 
the eBL patients, the tumor presenting site was 43% (12/28) jaw tumors and 57% 
(16/28) abdominal tumors. Regarding survival, the eBL samples included three 
patients who died before receiving any treatment, five patients who died during 
treatment, and 16 patients who were able to complete the recommended 
chemotherapy treatment with resolution of their tumor and discharged from 
hospital (Buckle et al. 2016b). In-hospital survival for the children included in this 
study was 64% (18/28). For each of the samples, we performed strand-specific RNA 
sequencing generating on average 14M paired reads per library (range 8.9-53.7M 
reads). All 30 samples in the sequencing set showed high expression of associated 
BL markers, including traditional cell surface markers CD19, CD20, CD10 and 
CD79A/B, and intracellular markers of MYC and BCL6, consistent with the 
molecular phenotype of BL (Ferry 2006b). All samples, including re-analyzed sBLs, 
showed high proportions of B cell specific expression (Abbas et al. 2005) consistent 
with adequate aspirates of the tumor cells. 
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Table 2.1 Summarized clinical information for sequenced endemic BL tumors. 
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2.3.2 EBV Positive eBL Tumors are Predominantly Canonical 
Latency I Expression Program 
In concert with human transcriptome analysis, we first checked if EBV DNA 
was present in the tumor isolates using quantitative PCR. As expected, the vast 
majority of eBLs was positive (93%, 26/28) while only two eBLs and the two sBLs 
were negative (Lazzi et al. 1998). For EBV positive tumors, viral load assays 
indicated that tumor cells contained multiple copies of EBV DNA (mean 4,475 
copies/ng tumor DNA; ~30 EBV/cell, median 1,542 copies/ng tumor DNA; ~10 
EBV/cell). We also determined the virus type using distinguishing primers against 
viral gene EBNA3C. We found that 31% (N=8) of the EBV positive tumors were 
infected with type 2 EBV genomes whereas 69% (N=18) of them carried EBV type 1 
genomes. We observed no mixed infection of both types of eBL tumors. 
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Figure 2.1 Expression heatmap for all known EBV genes for 26 eBL, four sBL and 
three long-term BL cultures (Daudi, Raji, Namalwa) that were found to be EBV 
positive. This correlation based clustering heatmap using log2 transformed FPKM 
values demonstrates a predominant expression pattern resembling latency I for 
most of the BLs while two eBLs (eBL_23 and eBL_25) and cell lines have elevated 
expression in other genes. eBL_02 and eBL_20 show intermediate levels lytic genes 
such as BMRF1, BALF2, and BSLF2/BMLF1 in addition to the two eBLs that 
cluster with cell lines. 
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Given that these two types have divergent genomic sequences for several 
genes, we mapped the RNAseq reads to the appropriate viral transcriptome 
sequences. EBV positive tumors demonstrated significant viral gene expression, 
regardless of viral genome type. This expression from the EBV genome ranged 
across a continuum with the average around 200 RPM (reads per million) (ranging 
from 10 to 400 RPM, cumulative viral reads per library). The two EBV negative eBL 
tumors and two sBL tumors did not demonstrate any EBV specific reads supporting 
the absence of the virus based on qPCR. Interestingly, viral DNA copy numbers did 
not correlate significantly with overall viral transcriptome activity levels. Along 
with BHRF1, BHLF1 and several EBV latent genes (EBERs, EBNA-1 and 
LMP2A/B) are weakly positively correlated with viral DNA levels in individual eBL 
tumors. On the other hand, BART transcripts, which are the most abundant 
transcripts including RPMS1, A73, and LF3, demonstrated no correlation with viral 
DNA levels. This suggests that the observed viral expression levels within tumor 
cells are for the most part independent of viral load or lytic replication rates and 
may be dependent on other factors. In addition to the eBL tumors, four of the sBL 
primary tumors that were re-analyzed were also EBV positive (14%) and carried 
type 1 EBV genomes. Overall, viral genes in eBL tumors demonstrated a 
predominant expression pattern consistent with the latency I. However, 
hierarchical clustering of viral genes revealed several potential subgroups (Figure 
2.1). All sBLs clustered separately and showed latency I pattern but increased 
levels of BALF3 and BARF0, unlike eBLs. The cell lines and three eBL samples 
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showed higher levels of most genes suggestive of increased viral replication and 
lytic activity. Among these three, two (eBL_02 and eBL_25) with elevated BHLF1 
and lytic gene expression were patients who died in-hospital before receiving any 
treatment. 
 
2.3.3 In-depth Assessment of Correlated Variation with Clinical 
Features and Viral Type 
Our initial question related to the tumor transcriptome was if there were any 
major expression differences and if any major differences correlated with the 
features of anatomical tumor presentation site, in-hospital survival or EBV type. 
After normalization of expression, we performed unsupervised hierarchical 
clustering based on Pearson correlations on expressed genes with the greatest 
variation (Figure 2.2). The overall correlations among eBLs were extremely high 
(r>0.96, average). The sporadic tumors which differed in the biopsy collection 
procedure (surgical biopsy or fine-needle aspirate) and preservation methods (fresh 
frozen or RNAlater) still showed a high-degree of correlation (r>0.90) with eBLs 
although they distinctly clustered away from eBLs. Similarly, the major principal 
components showed no discernible separation based on tumor presentation site, 
treatment outcome, and viral genome type. Overall, this suggests that eBL tumors 
are a relatively homogeneous group without overt subtypes based on tumor 
presentation site, survival or EBV type.  
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Figure 2.2 Sample to sample clustering of BL tumors based on expression profiles 
of top genes with the highest correlation of variation (CV) values (calculated using 
regularized log transformed expression data). While two sBLs (sBL_u1 and sBL_u2) 
separate out from 28 eBLs, eBL tumor expression profiles demonstrate greater 
correlation within eBLs (r > 0.95, Pearson correlation; Dark red is 1.0) compared to 
sBLs, which might be due to differences in biopsy and preservation methods or 
biology. Overall gene expression correlations between eBLs do not reveal significant 
clustering consistent with no major underlying molecular subtypes nor clustering 
correlating with tumor presentation site, treatment outcome, or EBV type. 
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We then checked individual genes for differential expression between eBL 
tumors with different clinical features. For tumor site, only NOS3 showed 
significantly (~2 fold) higher expression in abdominal tumors. This gene encodes for 
nitric oxide synthase 3 (aka eNOS) and is known to be more highly expressed in 
abdominal endothelial (Teng et al. 1998). Given the molecular phenotype of eBL 
tumors appears relatively homogeneous, it may be that unaccounted variation, 
biases or stochastic noise may be obscuring the detection of true expression 
differences. Thus, we used surrogate variable analysis (SVA) to isolate and remove 
unaccounted variation while preserving the variation associated with the feature of 
interest (Leek 2014a). As a result, we still failed to determine any significantly 
differentially expressed genes or pathways between biopsies from two different 
clinical tumor presentation sites, jaw and abdomen. However, for the in-hospital 
survival of those who commenced chemotherapy, we detected ten significantly 
differentially expressed genes between tumors of patients who survived and those 
who died (Figure 2.3A). AGPAT3, CTSL, ISCU, CTSD, and APOE showed greater 
relative expression in tumors of patients who survived while TUBB6, SLC25A24, 
FAM127A, HOMER1, and SLC12A3 demonstrated greater expression in tumors of 
patients who died. Gene set enrichment, and pathway analysis between expression 
profiles of these patient groups suggested several hallmark pathways including 
hypoxia, IL2/STAT5 signaling, MYC targets, and TNFα signaling via NFκβ. The 
leading edge genes ( the core of the enrichment signal) mutually shared by these 
hallmark gene sets are SERPINE1, CD44, ENO2, PLAUR, RHOB, and TNFAIP3. 
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These genes represent potential prognostic biomarkers requiring further 
investigation. 
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Figure 2.3 Clustering heatmap of significantly differentially expressed human 
genes between factors of phenotypes. Sample wise scaled log2 expression values 
range between lowest as light green and highest as dark red. Clustering 
dendrogram based on Pearson correlation demonstrates tumor grouping proper to 
the phenotype of interest. A) Significantly differentially expressed genes between 
Survivors and Nonsurvivors (BH Padj < 0.1). B) Significantly differentially 
expressed human genes between eBL tumors carrying EBV Type 1 and eBL tumor 
with EBV Type 2 (BH Padj < 0.1). 
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Comparison between EBV type 1 and type 2 viral-containing eBL tumors 
revealed 13 significant, differentially expressed genes (Figure 2.3B). Four out of 8 
genes that have significantly higher expression in eBL tumors with type 1 EBV are 
coding for the required components of immunoproteasome complex formation; 
PSMB9 (β1i), PSMB10 (β2i), PSMB8 (β5i), and PSME2 (PA28β). In addition, all of 
the other proteasome gene transcripts showed increased expression on average in 
eBLs with type 1 EBV. Consistent with this, our gene set enrichment and pathway 
analysis revealed several significant differential gene sets involving MHC class I 
antigen presenting cascades, ubiquitination, and proteasome degradation, and 
antigen cross presentation altered between type 1 and 2. This difference in 
expression of IFN-gamma inducible immunoproteasome complex genes and 
enriched pathways suggest that type 1 and type 2 genomes of EBV might differ in 
the pathogenesis of infection as well as in their roles promoting oncogenesis. 
 
2.3.4 Human Gene Expression Appears to be more 
Differentiated Based on EBV Status rather than eBL and sBL 
Geographic Designation 
We next investigated whether sBLs differ from eBLs regarding human gene 
expression profiles. While it is inherently challenging to compare samples that have 
been collected and experimentally processed with non-identical methods, we 
attempted to control for collection and processing differences by accounting for them 
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in the comparison sets using SVA. We included 7 BL cell cultures as well as two 
sBL primary biopsies from our sequencing set and observed proper clustering 
according to their eBL and sBL designations. Differential gene expression analysis 
comparing the only eBL and sBL primary biopsy samples resulted in 504 genes with 
significantly different expression profiles based on geographic BL subtype 
classification. Leading edge analysis following the GSEA of differentially expressed 
genes reoccurring in multiple Gene Ontology (GO) gene sets demonstrated that the 
genes involving biological processes such as vasculature or blood vessel 
development (BH Padj = 6.0 × 10-24) and angiogenesis (BH Padj = 4.0 × 10-23) are the 
major variation source between our eBL biopsy collections with FNA and sBLs with 
FFB. These dominant enrichment sets are likely associated with the different 
biopsy collection techniques rather than pathological distinctions. On the other 
hand, the differentially expressed genes between eBL tumors and sBL tumors also 
resulted in significant enrichments in Hallmark gene sets including apoptosis, 
IL2/STAT5 signaling, Notch signaling, KRAS signaling, and TNFα signaling via 
NFκβ. Leading edge genes in these hallmark sets point to strong differential 
expression of the PI3K-Akt signaling pathway (BH Padj = 3.0 × 10-23) which plays a 
central role in BL pathogenesis/oncogenesis (Kawauchi et al. 2009; Rickert 2013). 
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Figure 2.4 Gene set enrichment plot and expression heatmap of corresponding 
genes in the enriched gene set. Left panels include the running enrichment score 
throughout the gene set, and projection of genes in the gene set to the complete list 
of genes rank ordered based on the signal to noise ratio. Leading edge genes that 
build up the enrichment score of the geneset (RES at the peak) are the most 
important genes for these tumor sample comparison. On the expression heatmap 
(columns are tumors, rows are genes in the gene set), dark red represent higher 
expression while dark blue lower expression. A) Genes in this enrichment have 
been shown to be downregulated upon PTEN knockdown, and are observed to be 
downregulated in EBV positive BLs relative to EBV negative BLs (ES = 0.438, 
Nominal P = 0.00, FDR q = 0.0959) and B) Hallmark gene set enrichment showing 
mTOR complex 1 signaling genes to be relatively more activated in EBV positive 
BLs compared to negative BLs (ES = -0.439, Nominal P = 0.0665, FDR q = 0.151). 
Enrichment of genes associated with mTOR activation supports the enrichment of 
genes linked to PTEN inhibition. 
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Given that EBV presence is highly correlated with eBL tumors, we 
hypothesized that EBV might be a major determinant affecting differential 
expression between BL tumor subtypes. Therefore, we stratified our samples sets by 
their EBV content. Hierarchical clustering of the sample correlations demonstrates 
that we successfully preserved the variation associated with only BL tumors' EBV 
status and removed other unwanted covariates. As a sign of this, three EBV positive 
BL cell cultures as well as 4 EBV positive sBL tumors clustered with the rest of the 
EBV positive eBL tumors. Confirming this stratification, two EBV negative eBLs 
and two sBLs from our sequencing set properly clustered with the rest of the 
negative sBLs. We then performed differential gene expression and pathway 
enrichment analysis between the primary BL tumors, excluding the cell lines. This 
resulted in 1658 significantly differentially expressed genes between EBV positive 
and negative BL tumors. Increased number of significantly differentially expressed 
genes suggests that EBV presence in BL tumor affects host expression profile more 
dramatically than subtype designations based on geography. These differentially 
expressed genes highlighted functions in biological processes involving DNA 
replication, mismatch repair as well as cell cycle regulation pathways. Interestingly, 
gene set enrichment of the differentially expressed genes between EBV positive and 
negative BL tumors resulted in a significant enrichment in one of the oncogenic 
signature gene sets which consists of genes down-regulated when PTEN was 
experimentally knock-down (FDR q=0.096). Figure 2.4A shows the genes that have 
higher expression in EBV negative BLs compared to EBV positive BLs. This 
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suggests that EBV positive BLs, regardless of their geographic origin, share a 
common mechanism in which PTEN is suppressed. Supporting this, enrichment of 
another gene set in which genes are upregulated through activation of mTORC1 
(mTOR complex 1) suggests the loss of the regulatory role of PTEN in this signaling 
pathway in EBV positive BL tumors (Figure 2.4B). Combined these suggest 
increased activity of PI3K and subsequently AKT/mTOR pathway driving cell cycle 
and proliferation. 
 
2.3.5 Examination of Transcript Mutations 
We next explored the transcriptome for somatic mutations in eBL and 
compared it to previously sequenced sBL in order to investigate whether gene 
mutation frequencies diverge as well as gene expression profiles. After excluding 
the known genomic variants (SNPs), a total of 2728 putative somatic mutations 
were determined across the 56 tumor samples. Our carefully controlled variant 
detection allowed us to compare the gene mutation frequencies between eBL and 
sBL and clinical correlates (see Chapter III for details). This resulted in a total of 21 
genes mutated in 4 or more (>7%) of the sporadic and endemic tumors. 
Interestingly, the number of mutations did not differ significantly between sBL and 
eBL with an average of per tumor 3.6 vs. 4.1 genes mutated in eBL and sBL 
respectively (P = 0.24, t-test, 2-tailed). However, for the top ten most commonly 
mutated genes the difference was significant with 2.5 and 3.5 genes mutated per 
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tumor in eBL and sBL, respectively (P = 0.017, t-test, 2-tailed). Two of the top 3 
genes were equally mutated genes including MYC and DDX3X (Figure 2.5A, pink-
cyan bars). The mutation rates of the genes ID3, CCND3, TCF3, and SMARCA4 
were notably less frequently mutated in eBL tumors accounting for the difference 
between eBL and sBL. ID3 was significantly different, mutated in 32% of the eBL 
compared to 67% of the sBL (P = 0.007, Fisher's Exact). Also, 36% of the sBLs 
carried mutations in CCND3 compared to 14% of eBLs (P = 0.061, Fisher's Exact). 
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Figure 2.5 Mutational landscape of BL tumors. A) This panel demonstrates 
mutated gene distribution in each tumor sample (columns) are tumors, and rows 
are top frequently mutated genes (>10% of samples mutated at least once). Tumor 
samples were grouped based on their EBV content and second color bar shows the 
subtype of the tumor. Red squares represent mutated gene while blue is for no 
mutation detected. Barplot on the right measures the frequency of mutated tumor 
samples and compares regarding the subtype of BLs (Percent frequency). Similarly, 
bar plot on the left compares the mutated tumor frequencies for each gene stratified 
by EBV status (* P < 0.05, Fisher’s Exact). B) An average number of mutated genes 
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per BL tumor by EBV type. Error bars represent standard error (*** P < 0.01, t-
test). C) Schematic overview of the proposed key pathways and frequently and 
mutated genes in eBL pathogenesis. Genes in the boxes are found to be frequently 
mutated (gain of function and likely loss of function, represented by green and light-
red boxes, respectively). Likely key interactions with EBV components are shown in 
red connections. Possible interactions are shown in gray. 
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Given that ID3, TCF3 and CCND3 are thought to be key drivers for sBL 
oncogenesis, and eBLs do not carry mutations as frequent as sBLs, we hypothesized 
again that EBV might be already affecting these pathways abrogating the need for 
additional mutation. While EBV status is strongly correlated with endemic versus 
sporadic status, we re-analyzed the tumors based on the viral content to see the 
effect on the mutational spectrum. Interestingly, the difference in the frequency of 
the ten most common genes differentiated further to 2.4 to 3.7 for EBV positive and 
negative tumors, respectively. Only 196 out of 10,000 permutations, in which two 
eBLs and four sBLs were randomly assigned as virus negative and positive, 
respectively at each iteration, equaled or exceed the difference observed between 
EBV positive and negative tumors (P = 0.0198, t-test, 2-tailed). While individual 
genes in the simulation did not reach significance, CCND3, SMARCA4, and TCF3 
gene mutation frequencies showed further differentiation and reached significance 
by Fisher’s exact comparing EBV positive and negative tumors (P < 0.05 for each) 
(Figure 2.5A, yellow-green bars). Overall, these findings suggest that the molecular 
feature of gene mutations correlates better with the presence or absence of EBV 
within the tumor. Further supporting this, EBV negative BL tumors carried 
significantly more TCF3 or ID3 or CCND3 mutations (P = 0.0021), and there was 
only a single occurrence of more than one of these genes being mutated in EBV 
positive tumor compared with 11 EBV negative tumors. 
Apart from ID3, TCF3, and CCND3, two key genes SMARCA4 and ARID1A 
involved in chromatin and nucleosome remodeling as part of the SWI/SNF complex 
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are highly mutated. Interestingly, ARID1A was mutated in roughly equivalent 
levels in either categorization. In contrast, SMARCA4 demonstrates decreased gene 
mutation when comparing either eBL and sBL or EBV positive and negative. 
Furthermore, Ras homolog family member A, RHOA, the gene was mutated in 14% 
of eBL tumors in a mutually exclusive manner with TCF3/ID3 mutations. In 
addition, when we examined the mutations of two small GTPases, GNA13 and 
GNAI2, which are also recurrently mutated in DLBCL (diffuse large B-cell 
lymphoma) (Morin et al. 2013), this mutually exclusive mutation pattern among the 
BL tumors could be further extended to include mutations in GNAI2 (P = 0.005, 
Fisher’s Exact) but not GNA13. While this potentially suggests an alternative path 
for tumor drives other than deregulated ID3/TCF3, CCND3 and RHOA were not 
mutually exclusive potentially suggesting that the effects of CCND3 may be 
independent of TCF3’s drive. 
 
2.3.6 Novel mutated genes in eBL and clinical correlates with 
mutational status 
We identified several new genes that appear somatically mutated (Table 2.2). 
TFAP4, transcription factor AP-4, whose down regulation can protect against 
glucocorticoid-induced cell death (Tsujimoto et al. 2005) and appears to be involved 
in p21-myc regulation of the cell cycle (Jung and Hermeking 2009). TFAP4 carried 
five mutations in its HLH (helix-loop-helix) domain of likely deleterious effect, in 
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addition, to stop gain and start loss mutations. A new category of mutations seen in 
our analysis are genes involved in DNA repair including RAD50, PRKDC and 
MSH6. While such mutations are common in other cancers such as colorectal 
cancer, breast and ovarian cancer, and several autoimmune diseases (Mathieu et al. 
2015; Okkels et al. 2012; Heikkinen et al. 2003), they have not been reported 
previously in BL. Another previously undocumented gene showing somatic 
mutation was BCL7A. It has only been previously implicated in lymphoma through 
the observation of complex rearrangements (Zani et al. 1996) and its overexpression 
was associated with Germinal Center (GC) phenotype in DLBCL (Blenk et al. 2007). 
Interestingly, it is also a member of the SWI/SNF complex further highlighting the 
complex’s importance (Kadoch et al. 2013). Mutations in BCL7A, SMARCA4, and 
ARID1A were not observed to co-occur in either eBL or sBL. In addition, we 
detected mutations in the PRRC2C, RPRD2, FOXO1, PLCG2 that are normally 
overexpressed in peripheral blood mononuclear cells (PBMCs) and lymph nodes. 
We also examined the correlation of given mutations to clinical and molecular 
features. Supporting the lack of expression difference between tumor presentation 
sites, we observed no suggestive associations with mutations. A single gene GNAI2 
has a potential association with in-hospital survival (P = 0.021) where one out of 18 
survivors had a mutation in GNAI2 compared to three of five who died during 
initial hospitalization. 
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Table 2.2 Frequency of mutated genes in BL tumors classified based on EBV 
presence and genome type. 
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Fisher exact test P < 0.05 was denoted by * for type 1 vs type 2; † for type 1 vs EBV 
negative; ‡ for type 2 vs EBV negative BLs. Mutated BL tumor counts are in 
parenthesis. Abbreviations TF; Transcription Factor, BCR; B-cell Receptor, PBMCs; 
Peripheral blood mononuclear cells, DSBR; Double-stranded break repair, ALL; 
Acute lymphoblastic leukemia, CLL; Chronic lymphocytic leukemia, DLBCL; 
Diffuse large B cell lymphoma, NPC; Nasopharyngeal carcinoma. Gene description 
and functions are from NCBI/GenBank database. Mutations in other cancers are 
from the COSMIC database (http://cancer.sanger.ac.uk/cosmic). 
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2.3.7 Rates of Gene Mutations vary based on EBV genome type 
Regarding EBV type, PRRC2C, SMARCA4, PLCG2, and TFAP4 differed 
significantly (P<0.05). Interestingly, for these genes, type 2 EBV tumors always had 
the higher proportion of mutations compared to eBL tumors containing EBV type 1 
(Table 2). All of the mutations that TFAP4 carried were either deleterious (Met1?, 
Gln15*, Arg127*, Pro185Leu) or accumulated in the DNA-binding domain 
(Arg50Trp, Arg58Trp, Arg60Cys). These suggest a possible loss of function for the 
protein AP4 encoded by this gene mutated mostly in type 2 carrying eBLs (50%). 
SMARCA4 mutation rates in groups of BLs with type 1, type 2, and negative were 
roughly 5%, 38%, and 39%, respectively. Mutations in this gene were located in its 
important domains SNF2, helicase, and HSA domains. In general, the average 
number of mutated genes per tumor (including all 21 genes) was 2.9 in BL tumors 
infected with type 1 while 4.9 in BLs with type 2 EBV (P < 0.01, t-test, 2-tailed) 
(Figure 2.5B). This was significant even excluding type 1 tumors that were sporadic 
and also the overall type 2 mutation rate was on par with that of EBV negative 
tumors. The only genes that appear to have significantly lower mutation rates in 
type 2 tumors compared to EBV negative tumors were ID3 and TCF3, which were 
on par with type 1. Overall, functions of genes with distinct mutation frequencies in 
these groups, in addition to the significantly different general mutation rates, 
supports type 1 EBV’s reputation regarding better transformation ability compared 
to type 2, which had almost equivalent levels of mutated genes per tumor as EBV 
negative BLs (4.9 and 4.4, respectively). 
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2.4 Discussion 
Our major finding is that eBL is a homogenous tumor with highly correlated 
expression profiles, regardless of tumor location within the body. This means there 
is no need to create diagnostic subdivisions based on tumor presentation site or 
refine staging based on gene expression profiles. This contradicts previous 
expression analyses that suggested greater heterogeneity within eBL compared to 
sBL or id-BL  (Piccaluga et al. 2011b). Our unsupervised hierarchal clustering did 
not reveal major clades based on the virus, viral type, in-hospital survival or tumor 
presentation site. Our analysis of tumor presentation site suggested minimal 
differences that could be explained by associated cellular microenvironment (e.g., 
differences in endothelium presence, NOS3). On the other hand, gene expression 
comparison of tumors based on survival status of the patients revealed several 
candidate genes and gene sets providing potential prognostic biomarkers which are 
currently lacking for eBL. Survival rate difference could be attributed to delayed 
time to diagnosis of abdominal cases compared to more apparent facial tumors  
(Kazembe et al. 2003). Further studies are required to validate the clinical utility of 
such markers. 
The analysis presented here of BL patients from Kisumu, Kenya was underway 
when a similar study was published involving 20 Ugandan patients  (Abate et al. 
2015b). Therefore, we re-evaluated our analysis to determine if we could validate 
their findings. We found similar mutation rates in ID3 and TCF3 genes and 
associated these with the lack of EBV positivity. However, we observed less 
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frequent RHOA and no CCNF mutations in Kenyan eBL tumors. In contrast to the 
Ugandan study, we also failed to detect any significant trace of other herpes viruses 
such as KSHV or CMV other than EBV although this may be attributable to our 
FNAs which decrease the sampling of the connective tissue where these viruses 
were mainly present. Their study was also limited in its ability to examine EBV 
types for which we found significant differences in expression within our Kenyan 
tumors. The mutated genes we observed in BL tumors are also dysregulated or 
mutated in other cancer types with viral etiologies. DDX3X is activated by Hepatitis 
C Virus (HCV) leading to alteration of host cellular gene expressions  (Ariumi et al. 
2007). RHOA and CCND3 are dysregulated by Human T lymphotropic virus type I 
(HTLV-I)  (Marriott and Semmes 2005). For the DNA tumor viruses, KSV tumors 
appear to be driven by viral programming in settings of immunocompromised with 
only a few described driver mutations including interleukin 1 receptor-associated 
kinase (IRAK1) in primary effusion lymphoma  (D. Yang et al. 2014). In HPV-
associated squamous cell cervical carcinoma, the most common driver mutations are 
PIK3CA, EP300, TP53, FBXW7, and MAPK1  (Ojesina et al. 2014). PI3K mutations 
are common in epithelial derived EBV-positive nasopharyngeal carcinoma, with the 
most commonly somatically altered genes being TP53, CDKN2A/B, ARID1A, 
CCND1, SYNE1 and PI3KCA  (Lo, Chung, and To 2012)  (D.-C. Lin et al. 2014). 
While these are comparable with BL the targeting of the PI3K pathway, SWI/SNF, 
and p53, the overall differences suggest that even between EBV malignancies the 
major factor in determining what genes are the lynch pins between normalcy and 
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malignancy is the cell lineage and state. This concept is supported by the greater 
mutational commonality with other lymphomas and the fact that both virus positive 
and negative BL tumors have mutational commonality differing mainly in degree. 
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Chapter III. Experimental and Computational 
Framework for Studying Comparative Gene 
Expression and Mutations using RNA Sequencing 
Data 
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3.1 Summary 
In this chapter, I cover major experimental and computational techniques 
unique to RNAseq for comparative gene expression and mutational profiling 
studies. I briefly summarize important aspects of experimental designs, possible 
biases, and proposed approaches to correct them. I also explain the experimental 
and computational methods we used in our projects in detail with their reasonings 
for why we chose them. In addition to gene expression quantification, I also cover 
methods to accurately call spontaneous mutation sites in expressed protein-coding 
genes using RNAseq data. Furthermore, I provide a unique data analysis pipeline 
for PASseq (Polyadenylation site sequencing) datasets and how we approached this 
to utilize it for determining the polyA site isoform level expressions. This 
computational framework also allows users to identify significant alternative polyA 
site switches between different conditions. Finally, I provide the scripts and tools 
mentioned in these frameworks via GitHub to users who are willing to apply to 
their projects. 
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3.2 Accurate Measurement of Gene Expression 
3.2.1 RNA Isolation for Quantifying Expression Level 
Transcriptional processes produce a variety of RNA molecules which are 
classified based on their potential for coding for a protein sequence. Non-coding 
RNAs (ncRNAs) play distinct functional roles in various ways and mainly consist of 
transfer RNA (tRNA), ribosomal RNA (rRNA), long intergenic non-coding RNAs 
(lincRNAs), as well as small size RNAs such as small nucleolar RNAs (snoRNAs), 
microRNAs (miRNAs), or Piwi-interacting RNAs (piRNAs). Messenger RNAs 
(mRNAs), on the other hand, carry genetic information for assembling a protein 
which will function as an enzyme or a building block of a cell. In eukaryotes, 
precursor mRNA molecules go through post-transcriptional processing by splicing 
out intronic sequences in the nucleus. During the transcription, 5’-end of the 
molecules are modified with a methylated guanine nucleotide (5’-capping) to form a 
stable molecule and protect it from degradation. Another modification which affects 
almost all mRNAs is a process called polyadenylation which involves the addition of 
many adenosine nucleotides to the 3’-end of mRNAs. A subset of histone protein 
coding mRNAs, replication-dependent histones, are the known exceptions of polyA 
tailing and their 3’-end forms a step-loop instead  (Marzluff, Wagner, and Duronio 
2008). 
Although mRNAs and proteins are completely different molecules, the 
functional consequence of the proteins can be extrapolated by determining the level 
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of mRNAs in a cell. Both of these have a highly dynamic activity and are controlled 
via strict regulatory mechanisms. In addition to variation from gene to gene, cell 
type specific regulations and environmental factors play a major role in fluctuations 
of expression levels. Thus, gene expression measurement is not a trivial task. An 
expression level of a gene, Xijt, should be defined with its constraints as the number 
of mature mRNA molecules produced from a gene i, in cell j, at time point t. Proper 
measurement of this will allow us to predict functional consequences of proteins and 
to infer the faith of the system or phenotypic outcome. Therefore, methods for 
estimating expression levels have to be precise and produce results closer to reality. 
In order to determine mRNA levels, very first step is to reach molecules by 
disrupting the cellular structures and isolating RNA from the lysate. This delicate 
process is essential to maintain the integrity of RNA composition and 
characteristics. The quality of isolated RNA is usually assessed by checking the 
abundance ratio of 28S to 18S rRNA, which should roughly be 2:1, respectively. 
Departure from this proportion might indicate poor quality and degradation in 
isolated RNA. Most of the current RNA isolation techniques require enormous 
amounts of starting material from cells and tissues. As a result, isolated mRNA 
levels no longer pertain to individual cells composing tissue bulk rather represent 
an approximate average of them. Therefore, the expression level of a gene should be 
re-defined as Xiμt , where μ represents the average of all cells used in that isolation. 
One of the major issues faced with during the detection of expression levels of 
target RNA populations, generally mRNAs, is sampling inequality because of 
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naturally high abundant rRNA transcripts. rRNAs function as the key component of 
ribosome complex and comprise of approximately 80% of total RNA strains 
depending on cell type since they are produced by multiple repetitive and highly 
conserved loci of the genome. Abundant rRNA strains reduce sensitivity in 
expression measurements because of their dominance, and they are less informative 
unless specifically targeted for microbiome studies. Therefore, rRNA transcripts 
should be eliminated. There are two widely used techniques; the first one is 
selecting only RNA strains desired for expression measurement. Reverse 
transcriptase quantitative PCR (RT-qPCR) conducted using specific primers 
targeting unique gene sequences can be considered in this class. Microarray chips 
consist of many, as opposed to RT-qPCR, gene-specific hybridization probe 
sequences attached to a solid surface is another technique which has been used for 
expression measurement. Both of these are highly successful for eliminating rRNA 
and reaching the desired signal. An alternative method is a negative enrichment by 
removing with magnetic beads carrying hybridization probes on the surface 
designed specifically as complementary to rRNAs by utilizing conserved nature. 
However, this increases the cost of assay undesirably. 
For Burkitt lymphoma expression quantification study, we extracted genomic 
DNA and total RNA from FNA eBL biopsies stored in RNAlater and from sBL 
frozen biopsies stored in liquid nitrogen using Qiagen Allprep DNA/RNA/Protein 
mini kit (QIAGEN Sciences, Germantown, MD) according to manufacturer's 
instructions. Following the extractions, concentrations of nucleic acids were 
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measured with picoGreen (Thermo Fisher Scientific Inc.), and quality checked using 
NanoDrop. To further assess input total RNA quality and integrity, we ran 1ul 
extract on Agilent Bioanalyzer RNA Nano chip (Agilent Technologies, Waldbronn, 
Germany) and only included samples with RNA Integrity Number (RIN) higher 
than 7.0. 
 
3.2.2 Sequencing as a Method for Expression Measurement 
The emergence of sequencing technologies and reduced costs opened areas for 
new applications. Sequencing RNA transcripts (RNAseq) and determining the 
abundance levels is one of most common practices. Although there are multiple 
alternatives, Illumina short reads sequencing is widely preferred for this purpose. 
Sequencing DNA or cDNA using Illumina instrument requires a preparation of a 
library composed of fragmented pieces of sequences. Two primary methods are used 
to remove rRNA, as mentioned above, one of them is rRNA depletion technique, and 
the other one is polyA selection which enriches almost all mature polyadenylated 
mRNA transcripts using oligo-dT attached magnetic beads. Library preparation 
protocols also vary depending on the purpose of sequencing. However, the difference 
becomes apparent when it comes to preserving the transcription strand of RNA. 
Early standard Illumina protocols widely used produced non-strand specific 
libraries while improvements in protocols allowed maintaining original strand 
information  (Parkhomchuk et al. 2009). The most common strand specific RNAseq 
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protocol is based on utilizing dUTP in the second strand synthesis instead of dTTP; 
therefore it is called dUTP-method (details of this will be given later in this chapter)  
(Levin et al. 2010). One of the advantages of using a strand-specific RNAseq 
protocol is better expression quantification of, especially overlapping genes. 
Depending on the technique used during the library preparation, various biases can 
occur. Coverage biases towards the ends of transcripts emerge by using cDNA in 
fragmentation rather than RNA molecule  (Z. Wang, Gerstein, and Snyder 2009). 3’-
end bias also occur especially when polyA tail selected low quality or degraded RNA 
isolates are used in preparation. Both of these result in non-uniform distribution of 
read coverage of sequenced transcripts. Besides, extreme GC content of transcripts 
also affect their sequencing coverage and result in under-estimated expression 
levels compared to other moderate GC transcripts because of multiple PCR steps 
during the library preparation. 
If the desired experimental measurement is to determine gene expression 
levels, short-read Illumina sequencing, 36-100 nt, is commonly used. Although it 
has been found that there was little improvement in quantification when reads used 
longer than 50 nt, sequencing libraries with paired end significantly increased the 
isoform quantification quality because of the decrease in mapping ambiguity  
(Chhangawala et al. 2015). Target sequencing read depth per sample depends on 
experimental questions. For human gene expression quantification, 30 million 
reads/sample is enough, while for discovering novel transcripts and isoforms, 
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sequencing depth should be at least more than 50 million per sample  (Sims et al. 
2014).  
Starting with 1-5 ug total RNA, we isolated mRNA with oligo-dT using 
Dynabeads mRNA purification kit (Life Technologies). mRNA was fragmented with 
metal ions, and after the first strand synthesis with Superscript III, we marked the 
second strand by incorporating dUTP instead of dTTP. Then end-repair and A-
tailing steps were followed by Y-shaped Illumina adapter ligation step which 
maintains strand directionality. We size-selected libraries using XP Ampure 
magnetic beads (Beckman Coulter Inc.) selecting for a 330 bp insert size. Before low 
cycle PCR with High Fidelity Phusion polymerase (NEB) for amplification and 
adapter sequence completion, the second strand marked with dUTP was degraded. 
During the sequencing library preparation, we checked DNA quality and fragment 
size distribution using Bioanalyzer Agilent 1000 kit. Final library qualities were 
confirmed with Bioanalyzer Agilent High Sensitivity DNA kit and sequenced with 
paired-end read (2x100bp) using an Illumina HiSeq 2000 (Illumina Inc., San Diego, 
CA, USA). 
 
3.2.3 RNAseq Data Processing and Expression Quantification 
Qualities of raw sequencing reads were assessed by using FastQC  (Andrews 
2010). Reads were sorted by sample based on unique sample barcodes identified by 
Novobarcode (Novocraft Technologies, Malaysia). Residual Illumina adaptor 
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sequences on the 3' end of reads were trimmed using cutadapt  (M. Martin and 
Marcel 2011). Reads that mapped to ribosomal RNA using bowtie2 were removed  
(Langmead, Ben, and Salzberg 2012). 
There are various approaches for specific questions to answer with RNAseq, 
and each has its own challenges  (Garber et al. 2011). The first step towards 
determining the expression level of each gene is normalization by total sequencing 
depth which is the total amount of reads generated by the instrument. RNAseq 
method naturally produces more sequencing reads for longer transcripts. This 
property causes underestimation to occur towards shorter transcripts. Thus, read 
counts of each gene need to be normalized to the gene exonic length before 
comparing genes to each other. This method of normalization is abbreviated as 
FPKM (Fragments per Kilobase exon per Million reads) or RPKM (Reads instead of 
Fragments in the case of single-end). If we define number of read counts that gene i 
gets as Xi, and total number of reads that instrument generated for the library is N, 
then;  
CPMi =
  
      
, gives the library size normalized read count for gene i (Counts 
per Million), and 
FPKMi =
  
                    
 where Li represents the effective length of the gene i 
in Kb. On the other hand, there is an alternative normalization method proposed by 
Bo Li and Colin Dewey  (Li, Bo, and Dewey 2011b) called TPM (Transcripts per 
Million) which can be derived as 
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 TPMi =
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Although these correction methods take care of library sequencing depth and 
transcript length bias of RNAseq, they do not take GC content of transcript 
sequences into consideration. GC content becomes a factor needs to be considered 
especially when gene to gene expression comparison is required. Cqn R package 
provides functions that can be incorporated during FPKM calculations  (Kasper 
Daniel Hansen and Wu 2012). This way, generated gene expression matrix can be 
much more reliable especially when it is used for gene set enrichment analysis in 
which gene ranking plays an important role.  
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Figure 3.1 Overview of the RNAseq data analysis workflow. 
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3.2.4 Differential Gene Expression and Dealing with Batch 
Effects 
For differential gene expression analysis between two groups of samples or 
conditions, length or GC bias corrections are not required because, in such analysis, 
expression levels of different samples for each gene are compared rather than a 
comparison of genes to each other. Thus, most of the widely used testing approaches 
model gene expression by accepting raw read counts. After library size 
normalization, they fit read count distribution of each sample to Negative Binomial 
and perform a statistical test to determine significant expression changes. 
After preprocessing, we aligned read pairs to a transcriptome index built by 
RSEM  (Li, Bo, and Dewey 2011b) using Gencode version 19 protein-coding 
transcript annotations and hg19 genomic sequence. We calculated the expected read 
counts for each gene with strand-specific settings of rsem-calculate-expression. We 
used a union gene model which considers all possible isoforms and unionize to an 
inclusive gene model, which has the longest transcript structure. Fragments of 
transcripts that have varying GC contents tend to have different amplification 
efficiencies during the library enrichment. Therefore, after removing genes with all 
zero counts, genes were subjected to GC and transcript size normalization using 
functions in R package cqn (conditional quantile normalization)  (Kasper D. 
Hansen, Irizarry, and Wu 2012). These corrections were applied to FPKM 
calculations to generate normalized gene expression values. Genes that do not reach 
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to median 1.0 FPKM value for both of the conditions were excluded from that 
particular comparison. We then assessed the libraries separate batches and sample 
collection with principal component analysis and further corrected gene FPKM 
values for known covariates such as different batches using R package ComBat  (H. 
S. Parker et al. 2014). To perform differential gene expression analysis, we used 
DESeq2  (M. I. Love, Huber, and Anders 2014b) which fits the read counts to a 
negative binomial distribution and tests for significance using Wald test. Genes that 
are differentially expressed between conditions with were considered as significant 
with 10% FDR cutoff.  
To be able to account for the batch variables and unknown factors while 
testing for the differential expression, we estimated the number of underlying 
factors for every comparison separately using svaseq  (Leek 2014b) while preserving 
the variation of interest. This process involves identifying the surrogate variables 
using log-transformed expression data. Figure 3.2 shows the sample to sample 
clustering of primary BL tumor and cell line transcriptome profiles after removing 
the batch effect.  
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Figure 3.2 After removing the batch effect, clustering of samples correlate with 
their phenotypes. A) The sample to sample correlation heatmap of eBL, sBL 
tumors, and long-term BL cultures after removing all unwanted covariates except 
tumor origins. Gene expression profiles group into two clusters based on endemic 
and sporadic origins. 2 sBL biopsies that we sequenced (sBL_u1 and sBL_u2) and 
four originally sBL cultures group with the primary sBL biopsies while our 28 eBL 
biopsies cluster with Namalwa, Daudi, and Raji which have African origins. This 
clustering demonstrates that the expression variation preserved in the data set is 
solely unique to the origin of the BL tumor rather than different batches or EBV 
presence in the sample. Batch 1; primary biopsy samples that we sequenced, Batch 
2; primary sBL biopsies previously sequenced, Batch 3; previously sequenced long-
term BL cultures. B) The sample to sample correlation heatmap of eBL, sBL 
tumors, and long-term BL cultures after removing all unwanted covariates except 
EBV status of the samples. This time gene expression profiles result in two clusters 
based on EBV's presence or absence. EBV-negative BL cultures Ramos, BL41, 
BL70, and CA46 group with EBV-negative 26 sBL samples including two of our 
sBLs (sBL_u1 and sBL_u2). EBV-positive BL culture Raji, Namalwa, and Daudi 
cluster with EBV-positive eBL tumors as well as 4 EBV-positive sBL tumors. Again, 
this sample-wise clustering demonstrates that we have successfully removing 
unwanted covariants while preserving variable of interest, such as EBV status in 
this case. 
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We then adjusted the expression data by regressing the surrogate variables 
via matrix reconstruction. In parallel, to test individual genes for significant 
differential expression, we constructed the design of DESeq2 by incorporating these 
surrogate variables into the testing model. This enables to account for unwanted 
covariates without disturbing the assumptions of gene expression based on read 
count distributions in the process of testing for significance. 
 
3.3 Determining Mutations in Expressed Genes using RNAseq 
Although sequencing technologies improve rapidly, whole-genome DNA 
sequencing is still a costly method to detect genomic alterations and mutations. 
Because the majority of disease-associated single nucleotide variations (SNVs) occur 
in protein-coding regions, it is an appropriate approach to search for mutations in 
expressed exons using RNA-seq data. 
When a comparative analysis is performed regarding the mutation frequency 
differences using RNAseq, the expression level of the gene needs to be controlled. 
Since different cell types might have different expression profiles, this might occur 
as a differential coverage over exonic regions of genes. Thus, this should be 
controlled to avoid false negative calls from genes that are not naturally expressed 
under certain conditions or phenotypes. Besides, spliced aligners sometimes fail to 
align reads which span splice junctions correctly. Such reads create “dangling” read 
stacks at exon edges which often mismatch with the intronic sequence. Similarly, 
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RNA-editing sites are changes on transcribed mature mRNA molecules and often 
end up being called as mismatches relative to genomic reference DNA. All of these 
issues need to be carefully identified and appropriately handled when RNAseq data 
is used for SNV calling. 
In BL mutational profiling study, we started with preprocessing the RNAseq 
data. Redundant read pairs as a result of PCR amplification of libraries prior to 
sequencing were detected and removed using Picard tools  (Wysoker, Tibbetts, and 
Fennell 2013). Then, reads were mapped to reference genome hg19 using STAR 
spliced read aligner  (Dobin et al. 2013b) with a 2-pass approach to improve 
alignment across splice junctions. In the first pass, all reads are aligned to genome 
just to determine the splice junctions. Then, in the second pass, all of the reads are 
aligned to the same genome again with the help of detected splice junctions in order 
to increase read alignment rate, the sensitivity of spliced alignments, and overall 
coverage. In addition, for improved variation calling, we trimmed trailing bases 
with Phred quality scores less than 20 starting from 3' end of each read. To control 
for the differences in the sequencing depth between libraries, we randomly paired 
one eBL and one sBL tumor, and sub-sampled reads from the higher depth sample 
of a pair, so that the average depth per base for a pair was equivalent. We then 
called the single nucleotide variations (SNVs) using GATK. To assess the sub-
sampling performance, to ensure comparability, we examined the re-discovery rates 
of known germline SNPs included in dbSNP v146, which showed equivalent 
sensitivity for SNP call rates across the paired samples, with the average number 
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being slightly higher in eBLs compared to sBLs (6228 SNPs vs. 5690 SNPs, 
respectively). The frequency of detected non-synonymous mutations was also 
comparable. 
Following the standard workflow by GATK  (McKenna et al. 2010b) for 
calling variation with RNAseq data, we prepared alignments by processing reads 
that span intronic regions, realigning reads that carry InDels and recalibrating 
base qualities. After realignment and calibration of bases, we excluded reads that 
had low mapping quality (<20). Then, we called variations by utilizing the 
UnifiedGenotyper module in GATK with options -stand_call_conf 20.0, -
stand_emit_conf 20.0. In addition standard to remove SNP clusters of at least 3 
variants within 15nt window, we applied filter settings variance quality/confidence 
(QD < 2.0), mapping quality (MQ < 20.0), read depth (DP < 5.0), Phred-scaled p-
value using Fisher's exact test detecting strand bias (FS > 30.0). We also enforced 
conservative fragment depth counts instead of per read. Variants included in 
dbSNP version 146 and low-quality calls (mapping or base) were excluded. We 
limited variant calling to translated sequence of protein coding genes in GenCode 
annotation version 19. Due to their highly variable structures, we excluded 
immunoglobulin (IG_V), histocompatibility (HLA) genes, uncharacterized proteins, 
and known pseudogenes to reduce false calls. Splice region variation calls caused by 
failed junction spanning read alignments were filtered out in addition to variants 
overlapping with the repetitive regions (RepeatMasker, UCSC). Variant calls 
reoccurring at the exact genomic location with high frequencies also in the 
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lymphoblastoid cell line (LCL) RNAseq datasets were considered as possible 
artifacts due to mismapping, undocumented variation, or RNA editing and were 
excluded. The effect of the variations was predicted as “low,” “moderate,” and “high” 
using snpEFF  (Cingolani et al. 2012) based on protein sequence changes. 
  
3.4 End Sequencing as an Alternative to Full-length RNAseq 
As new sequencing technologies emerged, new techniques for targeting 
specific molecules and sequencing their content also specialized. For example 
degradome-seq (aka PARE; parallel analysis of RNA ends), RACE (rapid 
amplification of cDNA ends), etc. are modified specific sub-versions of full-length 
RNA sequencing. These methods not only enrich specific molecular strains but also 
produce higher coverage over the targeted transcript regions. Depending on the 
experimental questions, these methods provide sequencing read slightly different 
than conventional RNAseq methods. Thus, the data generated using such methods 
might require special care or alternative analysis methods. Polyadenylation Site 
sequencing (PASseq) is also a method for sequencing only the 3’-end of mRNA 
molecules for expression measurement purposes  (Shepard et al. 2011). As it is 
evident with its name, this unique sequencing library preparation method utilizes 
polyadenylation of mRNAs and targets the tails with oligo-dT for enrichment. 
Sequencing often is done with single-end and reads usually span mRNA cleavage 
site. Thus, poly-A stretches in sequencing reads need to be trimmed before 
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processing further. One of the major issues with this protocol is the enrichment 
approach. Genomic DNA or transcribed RNA body sequence can also contain poly-A 
stretches. These cause problems when hybridization oligo-dTs are used to pull down 
the molecules. These false enrichment products need to be identified in silico after 
sequencing and processed with cautious. One of the other purposes of choosing this 
method is to determine precise locations of the cleavage site, aka poly-A site. This 
allows researchers to study alternative poly-A site usage under certain conditions 
and determine site switch events which can be associated with any other phenotype. 
However, determining these locations with high precision requires special data 
processing and analysis. Here, we developed an analytical framework to investigate 
alternative polyadenylation site changes. We implemented this analysis pipeline in 
multiple programming languages, named it as “PoolPASS,” and applied it to 
several projects.  
 
3.4.1 PASSeq Library Preparation and Sequencing 
Although there are various versions of PASseq library preparation, one 
example is as follows which mostly adapted a previously published method for 
making libraries from RNA fragments  (Heyer et al. 2015). Total RNA integrity was 
first confirmed by agarose electrophoresis, and polyA tailed RNA was enriched by 
hybridization with oligo-dT. Following the enrichment, RNA samples were then 
fragmented to 60-80 nt size via chemical hydrolysis and reverse transcribed with 
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oligonucleotides containing forward and reverse Illumina sequencing primer sites 
separated by a hexa-ethylene glycol spacer (Sp18) linker. At the 5′ end, each 
oligonucleotide began with 5'p-GG to promote ligation, followed by five random 
nucleotides (unique molecular index, UMI) to enable PCR duplicate removal. Each 
primer also harbored a unique five nt Hamming barcode (BC), allowing for sample 
multiplexing. Following cDNA circularization with CircLigase I, libraries were PCR 
amplified (12-14 cycles) and subjected to single-end 100 nt sequencing on the 
Illumina HiSeq platform. 
 
3.4.2 Data Analysis with PoolPASS 
The primary goal of the analysis framework is to accurately measure 
expression levels of each mRNA isoform using PASseq data. This is achieved by 
three major steps; first is to preprocess sequencing reads and cleaning the 
background noise. The second step is to determine and remove internal priming 
locations. Then, the third step is clustering candidate locations in proximity to 
putative cleavage sites and reporting normalized expression levels of each location. 
Figure 3.3 demonstrates an overview of the PoolPASS analysis framework. The 
novelty of our approach is to process all samples in parallel and then to pool all 
candidate polyA locations together for further evaluations. This allows capturing all 
possible sites to be considered and prevents to miss any rare site switches. For 
example, a polyA site can be used in only one cell type or under certain conditions 
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and not used at similar levels in another. This pooling scheme we implemented 
allows lining up all putative locations for every sample and accurately comparing 
their expression levels. 
 
 
Figure 3.3 Overview of PoolPASS analysis framework. 
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After quality controlling with FASTQC  (Andrews 2010), we removed PCR 
duplicate reads using their unique molecular indexes (UMI). Using cutadapt  (M. 
Martin 2011), we then trimmed residual adaptor/spacer sequences and poly-A 
stretches from read 3' ends and mapped the reads to the hg19 reference genome 
using Bowtie2 (with parameters –m –best –p4). Only uniquely mapping reads with 
high-quality scores (>20) were used for further analysis. We defined the 
polyadenylation cleavage site as the base closest to the poly-A stretch captured 
within read sequence, thus, very last base at the 3’-end site after the trimming. 
Based on this, we calculated read coverage of every genomic location considering 
only 3’-end of the aligned reads. This forms a sharp peak of read coverage around 
the cleavage sites with an average width 40nt (ranging between 1nt-120nt). We 
then clustered sites that are in proximity closer than the 40nt window and summed 
the counts of clustered sites. In order to determine all possible PAS, which might 
differ from sample to sample, we pooled all candidate locations of all samples and 
reiterated the clustering using the same window length. Since genomic DNA 
containing poly-A stretches can be hybridized and pulled with the oligo-dT primers, 
aka internal priming, we used a Naïve Bayes classifier  (Sheppard, Lawson, and 
Zhu 2013) based software to determine the likelihood of all sites being false priming 
sites. In addition to filtering internal priming locations based on this, we also 
removed background noise caused by widespread base level read alignments by 
fitting the count distribution of each gene to Poisson distribution. After determining 
precise PA locations, we then calculated expression/read counts of every PAS for 
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each sample and annotated using Gencode v19. We also marked known polyA sites 
with PolyA DB (http://exon.umdnj.edu/polya_db/). For differential gene expression 
tests, we used the sum of all PAS counts of each gene and calculated library sizes 
based on this. The raw read counts for genes were used as an input for differential 
gene expression analyses using DESeq2  (M. I. Love, Huber, and Anders 2014c) in R 
(https://www.R-project.org). The default normalization using 'estimateSizeFactors' 
function was used. Adjusted p-values were calculated using the Benjamini and 
Hochberg (BH) method  (Benjamini and Hochberg 1995). In order to determine 
significance levels of alternative polyA site switches, we constructed a two by two 
contingency table composed of mean normalized read counts of one site and the 
average of rest of the sites, if there are multiple, in each of the conditions. We tested 
the significance with Chi-square test for given site and iterated through all sites of 
the gene. We then corrected p-values for multiple hypotheses testing using BH 
method.  
Code can be reached at https://github.com/yasinkaymaz/PoolPASS.git  
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Chapter IV. Studying EBV genomes in clinical 
specimens: from wet lab to in silico 
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4.1 Summary 
 
This chapter covers commonly used DNA sequencing methods and a variety 
of approaches developed to solve technical challenges faced with during whole 
genome assemblies. We established a workflow comprising of the targeted hybrid 
capture enrichment of viral DNA from the clinical specimens and high-throughput 
sequencing with next-generation sequencing technology. Analysis of individual EBV 
genomes consisted of de novo genome assemblies, variation and recombination 
detection followed by comparative phylogenetic tree constructions. 
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4.2 Introduction 
Applications of sequencing methods in clinical and translational sciences are 
wide. For example, a patient can be screened through time for diagnostic purposes 
during or after chemotherapy treatment by sequencing DNA circulating in the 
bloodstream  (Rapisuwon, Vietsch, and Wellstein 2016). A pathogenic outbreak can 
be resolved by tracking infected patients and finding patient zero with the help of 
sequencing  (Gire et al. 2014). Another example is that sequencing many pathogen 
genomes assist vaccine development efforts by deciphering divergent or conserved 
sequences. 
Sanger sequencing method has opened many opportunities. The human 
genome project was completed with shotgun sequencing. Sanger sequencing is a 
reliable technique with a low error rate. However, sequenceable DNA fragment 
length, which is a couple kb/run, is limiting. Given average length of a genome or a 
target genomic region is much bigger, the cost of using this method for one sample 
is very high. Here, next generation sequencing (NGS) comes into play which solves 
the problem with massively parallel sequencing. In addition, sequencing cost with 
NGS rapidly reduces day by day allowing users to generate more data and create 
new applications. 
Targeted sequencing is one of these applications developed for reducing the 
cost further down and sequencing only the DNA of interest rather than generating 
redundant data. One advantage of using targeted approach is that it significantly 
improves the sensitivity of sequencing which allows users to design experiments 
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involving metagenomic screens and to study heterogeneity in clinical samples. 
Tumor evolution and heterogeneity is one of these areas improving in the light of 
targeted sequencing approaches and sensitive assays. Researchers are often 
interested in determining the multiplicity of infection (or complexity of infection) 
levels when dealing with an infectious disease. A targeted approach with increased 
sensitivity allows us to detect multiple strains infecting the same individual. We 
could not even imagine this when the first human genome project was completed at 
the end of 20th century.  
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Figure 4.1. Repetitive Structure of EBV genome. 
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EBV genome is a 172 Kb DNA which is in linear form when encapsidated. 
Upon infection, the linear genome becomes circularized at the terminal repeats 
region to protect itself from cellular exonucleases. It has four large repeats regions 
IR1 to IR4 and short repeat regions (see Figure 4.1). Other than being repetitive, 
these regions reach up to 80% GC content elevating the overall genomic GC percent 
to 60%. On the other hand, although the multiplicity of infection is commonly 
observed, the viral genome abundance is still too low compared to the human 
genome. Unless viral replication is triggered through lytic reactivation, viral DNA is 
at negligible levels in the cell. In addition, EBV mainly persists in B cells of healthy 
individuals, and they typically carry 1-50 EBV positive cells out of 1,000,000 B 
lymphocytes  (Khan et al. 1996), which makes abundance even smaller when whole 
blood is considered. All of these make EBV genome studies challenging and 
sometimes impossible. Therefore, here in this chapter, I outlined an experimental 
and computational methodological framework for studying pathogen genome 
sequences in the context of Epstein Barr virus and provided solutions to overcome 
several challenges (see Figure 4.2). 
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Figure 4.2 EBV sequencing Pipeline overview. 
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4.3 Targeted Pathogen Genome Sequencing  
There are multiple ways to sequence pathogen genomes. In molecular 
biology, newly developed techniques let us manipulate DNA composition of samples 
and specifically work with certain DNA types. One of the sequencing approaches is 
metagenome sequencing which involves sequencing all types of DNA molecules 
present in the sample. However, depending on their relative abundance, the 
likelihood of getting a good quality sequence of every DNA strains varies. Thus, 
sensitivity decreases dramatically to low levels for some pathogen genomes because 
of highly abundant other, mostly host, genomic DNAs. To overcome this issue, 
culturing cells and pathogens organisms for producing abundant DNA is one option. 
This approach relatively increases pathogen DNA abundance, however; it might 
introduce bias to an experimental design by promoting only replication competent 
strains thus by losing natural mixture frequencies. One other approach is 
conventional PCR method to increase target DNA amount before sequencing, aka 
amplicon sequencing. PCR requires prior information about the target sequence to 
design primers this it can only be applied to already sequenced genomes. The most 
significant limitation of conventional PCR, which requires abundant template 
material, is the size of the target region that can be amplified. In addition, it is 
difficult to target and amplify highly variable and polymorphic DNA regions. This 
limits sequencing to certain regions and requires multiple reactions in case whole 
genomes are desired. Optimization and balancing all PCR products make 
conventional amplicon sequencing approach very challenging and labor intensive.  
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Recent developments in molecular techniques improved enrichment methods. These 
enrichment techniques were initially applied in exome capture sequencing studies 
in which only known exonic regions of genomes, roughly 1%, are sequenced. Short 
single stranded RNA molecules carrying covalently attached biotin called RNA baits 
or probes complementary to exonic regions in a tiling fashion allows hybridizing 
genomic DNA in a solution. Then, a pulldown with a streptavidin attached magnetic 
bead is used to select only DNA:RNA hybrids with biotin specifically. This 
technique dramatically increases sensitivity and read coverage of the targeted 
regions. Although, it also requires prior sequence and content information about the 
targeted genomes, the dynamic hybridization of RNA baits to target DNA can 
tolerate mismatches or polymorphic sites. This way, more variation can be captured 
in the DNA mixture.  
 
4.4 An Algorithm for Designing Hybrid Capture Bait Sequences 
Although hybrid capture probes are more tolerant for mismatches as opposed 
to conventional PCR primers, they also have a limit for mispairing. Highly 
divergent sequences can possibly be missed or at least captured with low efficiency. 
Therefore, the optimization of such hybrid capture probe sequence design is 
essential. For this purpose, we developed an algorithm and implemented it as a tool 
for users to design their own probe sequence set for desired genomes with increased 
sensitivity. We developed this with certain improvements in communication with 
Agilent Inc. representatives. Here, the purpose is to create custom design RNA bait 
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sequences targeting specific genomes or regions. In addition to the reference 
sequence, another source of sequences for the same target can be included to 
compensate for rare sequence variations like mutations, indels, etc. For example, 
these probes can also be produced using the genomes of cultured lab strains. The 
main steps implemented in the algorithm are as follows; 
 
1. Input multiple target genome sequence as a fasta file. 
2. Check cross-hybridization with Blast and mask regions homologous to 
human. 
3. Create candidate probe sequences with user defined parameters such 
as tiling (2X, 3X, 4X, etc.), length of the probes (default: 120 nt) 
4. Calculate GC content and an annealing temperature of each candidate 
probe sequence. 
5. Map candidate probes back to target genome. 
6. Check for mapping and alignment quality (repetitive regions or 
mismatch rate) 
7. Filter candidate probes with mismatch rates above given threshold. 
8. Calculate expected coverage of target window. 
9. Create new probe sequence for low coverage regions. 
10. Update the set of probe sequences 
11. Repeat 2.-10. Iterate through all input target genomes. 
12. Boost up probe numbers depending on GC content and annealing 
temperature. 
13. Output bait sequence set. 
 
Code is available at 
https://github.com/yasinkaymaz/TackleBox/TargetProbeDesign_pipeline.py 
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This tool can be used for any pathogen genome especially when increased 
sensitivity for mixed infections is desired. We first tested it with EBV strains. In 
addition to type I (NC_007605) and type I reference genomes (NC_009334), we 
included recently sequenced Mutu I, Akata, GD1 and GD2 sequences in in-silico 
probe design. The overlapping probes were 120 nt in length tiling across the 
genomic sequences at least four times. As a result, we created 6,564 unique probe 
sequences with a various number of representations based on GC content of the 
target regions. A total of 55,000 biotinylated RNA oligos were ordered for capture 
reactions and produced by MyBait Mycroarray Inc. 
 
4.5 Experimental 
4.5.1 Whole Genome Amplification 
One of the applications of targeted deep sequencing is the detection of all 
known drug-resistant pathogen strains in clinical samples as frequently practiced 
with CMV or influenza. Whole genome sequencing provides various useful 
information such as antigen epitope sequences, evidence for recombination between 
sub-strains, or novel drug-resistant variants. Studying viral genomic evolution in 
patients over time and changes to epitopes can be feasible with whole genome 
sequencing. Deep sequencing refers to a genomic sequencing with the extremely 
high depth of coverage. Since the number of reads generated by the instrument is 
proportional to the content of the DNA in the library, increasing the sequencing 
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depth allows detecting low frequent strains with better sensitivity. In some 
situations, pathogen strains carrying variants with less than 1% can be quickly 
dominant under certain selective pressures such as drug treatment. Therefore, 
detecting all variants ultimately in the mixture for example at early stages of 
treatment would be vital. 
Some species are hard to isolate and culture. Often, culturing is not desired 
since there is always a chance to bottleneck and select only sub-strains that are 
replication competent. Therefore, alternative molecular techniques are explored to 
recover or increase the abundance of desired genomes. Whole genome amplification 
with multiple strand displacement does not necessarily increase the sensitivity in 
favor of pathogen genomes since it happens randomly. Besides, genomic regions 
with high GC content might be underrepresented. Thus, amplification of EBV which 
has extreme GC content regions (reaching up to 80%) is problematic. Illumina 
sequencing relies on cluster generation with amplification and extension based 
sequencing which also affect read representation of such regions. Selective whole 
genome amplification (sWGA) is a method that utilizes target specific oligos rather 
than random hexamers. This method has been suggested by Leichty et al. 2014 and 
takes advantage of more or less specific motif sequences by using them as primers 
for amplification. The method also uses phi29 polymerase which works at 
isothermal temperature with high fidelity, 100 times less error rate than regular 
Taq polymerase, which also makes it appealing for whole genome sequencing. 
Strand displacement activity of phi29 allows it to be progressive, and it can amplify 
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up to 70kb products. Multiple strand displacement with target specific oligos leads 
to rapid branching and quick amplification. 
 
4.5.2 Preamplification PCR and Selective WGA 
In order to evaluate whole genome amplification techniques and optimize for 
EBV genome sequencing, we conducted multiple experiments with various reaction 
conditions. We conducted experiments to improve and optimize reactions. Then, we 
tested this method on cultured cell line DNA and primary clinical specimens. BL 
culture cells, Namalwa, Daudi, Raji, and Jijoye were grown in a complete growth 
medium, RPMI 1640 (Life Technologies), with 2mM L-glutamine adjusted to 
contain 1.5g/L sodium bicarbonate, 4.5g/L glucose, 10mM HEPES, and 1.0mM 
sodium pyruvate, 92.5%; fetal bovine serum, 7.5%. Blood samples were collected on 
the admission of the patients before treatment with chemotherapy, and the samples 
were stored at -80C prior to DNA extraction. FNA biopsies were transferred into 
RNAlater immediately after collection and stored at -20C. Genomic DNA was 
extracted from cultured cells and FNA biopsies stored in RNAlater using Qiagen 
Allprep DNA/RNA/Protein mini kit (QIAGEN Sciences, Germantown, MD) 
according to manufacturer's instructions. DNA from plasma samples were extracted 
using Qiagen Qiaamp DNA Kit. Prior to library prep or amplification, DNA extracts 
were purified with 2x XP-Ampure magnetic beads to remove residual inhibitory 
chemicals that may be introduced during the extraction process.  
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As standard whole genome amplification, we majorly followed the 
manufacturer’s instructions for whole genome amplification with Genomiphi v2 kit. 
We used 20 ng template DNA for amplification and incubated at 30C for 16h. Before 
and after genomic amplification of samples, the ratio of viral genomic copy number 
to human genomic DNA was checked with bi-plex qPCR using EBV specific primers 
against BALF5 gene and human beta-actin gene. Overall DNA quality and 
quantities were assessed with NanoDrop and Picogreen. The challenge was to 
increase EBV amplification yield by increasing the EBV to human DNA copy ratio 
after whole genome amplification. In order to overcome this challenge, we replaced 
the random hexamers required for MDA with EBV genome specific oligos designed 
specifically for isothermal temperatures. We designed the oligo sequences using a 
script provided by Leichty et al. using human genome as a background and EBV as 
the foreground. We ordered the oligos with 3’-end modification to protect from 
exonuclease activity of Phi29. See appendix for protected oligo sequences. 
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Figure 4.3 The effect of modified dNTP composition on GC high region coverage. 
Modifying the composition of deoxyribonucleotides in dNTP increases the EBV 
genomic coverage over GC high regions. 
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Table 4.1 Optimization of selective EBV whole genome amplification reaction conditions. Various factors such as 
dNTP composition, the amount of template DNA, denaturation buffer, incubation time and temperature were tested. 
  
Optimization 
EBV Copy 
input per 
20ng DNA for 
sWGA 
Denaturation 
Buffer 
Input EBV 
copy/uL 
(Average) 
Input B-
actin/uL 
(Average) 
dNTP 
composition 
(G/C/T/A) 
Incubation 
Output EBV 
copy/ ng DNA 
Output B-
actin/ng DNA 
 (EBVpost / 
EBVpre) / 
(DNApost / 
DNApre) 
 (Humanpost / 
Humanpre) / 
(DNApost / 
DNApre) 
Sensitivity, 
dNTP 
Composition 
10,000 TE 62,448 3,456 30/30/10/10 16h at 30C 4,573 7 1.06 0.03 
1,000 TE 10,038 13,911 30/30/10/10 16h at 30C 505 59 1.01 0.08 
100 TE 467 10,883 30/30/10/10 16h at 30C 55 70 2.28 0.12 
10 TE 10 11,326 30/30/10/10 16h at 30C 4 68 8.26 0.12 
1 TE 6 19,483 30/30/10/10 16h at 30C 0 55 0.21 0.06 
0 TE  11,551 30/30/10/10 16h at 30C  76  0.23 
10,000 TE 62,448 3,456 30/30/5/5 16h at 30C 4,847 2 1.12 0.01 
1,000 TE 10,038 13,911 30/30/5/5 16h at 30C 544 75 1.09 0.11 
100 TE 467 10,883 30/30/5/5 16h at 30C 72 65 3 0.12 
10 TE 10 11,326 30/30/5/5 16h at 30C 3 65 5.97 0.11 
1 TE 6 19,483 30/30/5/5 16h at 30C 0 81 0.22 0.09 
0 TE  11,551 30/30/5/5 16h at 30C  71  0.21 
10,000 TE 62,448 3,456 15/15/5/5 16h at 30C 3,483 16 0.81 0.07 
1,000 TE 10,038 13,911 15/15/5/5 16h at 30C 488 84 0.97 0.12 
100 TE 467 10,883 15/15/5/5 16h at 30C 73 109 3.04 0.19 
10 TE 10 11,326 15/15/5/5 16h at 30C 1 80 2.71 0.14 
1 TE 6 19,483 15/15/5/5 16h at 30C 0 103 0.25 0.11 
0 TE  11,551 15/15/5/5 16h at 30C  118  0.35 
10,000 TE 62,448 3,456 15/15/2/2 16h at 30C 3,324 12 0.77 0.05 
1,000 TE 10,038 13,911 15/15/2/2 16h at 30C 533 77 1.06 0.11 
100 TE 467 10,883 15/15/2/2 16h at 30C 78 105 3.24 0.19 
10 TE 10 11,326 15/15/2/2 16h at 30C 4 105 7.8 0.18 
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1 TE 6 19,483 15/15/2/2 16h at 30C 0 110 0 0.12 
0 TE  11,551 15/15/2/2 16h at 30C  108  0.32 
Denaturation 
Buffer, 
Incubation 
time and 
temperature 
10 TE 10 11,326 30/30/5/5 8h at 30C 2 40 6.31 0.14 
10 TE 10 11,326 30/30/5/5 16h at 30C 2 40 8.74 0.14 
10 TE 10 11,326 30/30/5/5 8h at 35C 1 22 4.05 0.08 
10 TE 10 11,326 30/30/5/5 16h at 35C 2 22 6.14 0.08 
10 TE+Q sol 10 11,326 30/30/5/5 8h at 30C 2 41 9.44 0.14 
10 TE+Q sol 10 11,326 30/30/5/5 16h at 30C 3 60 13.94 0.21 
10 TE+Q sol 10 11,326 30/30/5/5 8h at 35C 3 28 10.72 0.1 
10 TE+Q sol 10 11,326 30/30/5/5 16h at 35C 4 49 15.13 0.17 
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One of the possible reasons for low amplification yield of EBV DNA is the GC 
content of the genome. Therefore, we put this fact into the center of our 
optimization efforts and tested various parameters accordingly. We hypothesized 
that if we change the ratio of deoxyribonucleotides used in reactions in favor of 
guanine and cytosine, the polymerase will get a higher chance to proceed when it 
reaches to high GC regions of DNA. To test this hypothesis, we conducted 
experiments with varying deoxyribonucleotide compositions such as 30/30/10/10 or 
30/30/5/5 for dG/dC/dA/dT in the same order. We found that 30/30/5/5 composition 
yields relatively better EBV amplification which we measured as an increase in 
EBV DNA copy over the increase in human DNA copy (see Figure 4.3 and Table 
4.1). We also tested low copy template DNA with serially decreasing input EBV 
copies to determine sensitivity level of the amplification. Our results show that we 
were able to successfully amplify ten genomic copies per 20 ng total input DNA with 
almost six fold increase. Since we aimed to optimize amplification yield by adjusting 
conditions for GC rich contents, we tested Q-solution provided by Qiagen to 
determine if it improves overall yield. Compared to using TE buffer in template 
denaturation using Q-solution significantly increased the amplification yield for 
EBV genome. We also tested various incubation time and temperatures relying on 
the fact that elevated temperature might help to keep denatured DNA free of 
tertiary structures. We found that increasing isothermal incubation temperature to 
35C from 30C, and 16 hours longer incubation yielded slightly better (see Table 
4.1). However, we decided to proceed with the recommended temperature for Phi29 
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because thermostability of the enzyme needed to be monitored and further 
validation experiments required. Nevertheless, this suggests that the reason for 
under-representation of EBV genome DNA is most likely its high GC content when 
whole genome amplification method is used, and this further supports our 
hypothesis above. 
Even though we improved the amplification yield by optimizing reaction 
conditions for EBV genome (see appendix for reaction conditions), this overall slight 
increase does not result with final virus DNA amount enough for library 
preparation and sequencing. At this point, we decided to test one approach involves 
conventional PCR primers designed for EBV genome. We named this approach as 
“Preamp” which stands for the preprocessing step right before whole genome 
amplification. In this pre-amplification, we utilized multiple pools of primers and 
conducted low cycle number PCR to boost up target DNA. We hypothesized that this 
preamp step would increase the template amount for the following specific whole 
genome amplification reaction. We borrowed primers sequences from  (Hin Kwok et 
al. 2012a) and added a few new primers to be able to capture type 2 EBV strains 
(see appendix for primer pools). We observed that three separate pools of non-
overlapping PCR primers work better compared to one single pool of all tiling 
primers. We tested varying cycle numbers 5, 10, 15, and 20 for the preamp. We 
found that increasing cycle number also increases hybrid capture efficiency and 
sequencing read coverage. However, increasing it further might also cause overly 
non-uniform read coverage distributions which produce shorter assembly amplicons 
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(will discuss in the following parts). Therefore, we found 20 cycles as optimum for 
preamp reaction (see appendix for preamp reaction conditions). We also tested 
forward only or reverse only primers. Although the amount of yield was high with 
single primers compared to paired primers, the coverage distribution of those was 
extremely non-uniform which is not desired for genome assembly (see Figure 4.4 
and Table 4.2). In addition, we also tested three different polymerases, HotStar 
Taq, Long Range PCR polymerase, and Phusion. We found that the best working 
polymerase is Long Range PCR polymerase as expected because the average 
amplicon length is around 4.5Kb. 
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Figure 4.4 Sequencing coverage distribution over EBV genome comparing preamp-
sWGA libraries with different cycle amplifications. 
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Table 4.2 Sequencing read statistics comparing preamp-sWGA libraries with 
different cycle amplifications. 
 
  EBV EBV HUMAN HUMAN 
 READS 
READS 
ALIGNED 
% READS 
ALIGNED 
READS 
ALIGNED 
% READS 
ALIGNED 
Raji 287,091 259,209 90.29% 24,592 8.57% 
Raji_GP 1,270,227 1,040,137 81.89% 209,533 16.50% 
Raji_GP_GC 530,698 417,933 78.75% 103,691 19.54% 
Raji_Mix-1_sWGA 348,350 319,903 91.83% 22,757 6.53% 
Raji_Mix-2_sWGA 376,570 356,406 94.65% 8,425 2.24% 
Raji_5cyc_sWGA 2,451,526 250,133 10.20% 2,141,720 87.36% 
Raji_10cyc_sWGA 642,930 194,795 30.30% 434,507 67.58% 
Raji_15cyc_sWGA 1,014,156 506,977 49.99% 480,917 47.42% 
Raji_Fw_sWGA 1,728,634 1,451,336 83.96% 237,268 13.73% 
Raji_Rev_sWGA 6,245,778 5,081,132 81.35% 934,634 14.96% 
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4.5.3 Sequencing Library Preparation and Target enrichment 
We prepared Illumina sequencing libraries using a custom protocol (see 
appendix B). Briefly, the protocol consists of steps for DNA shearing, blunt end 
repairing, 3'-adenylation and indexed sequencing adaptor ligation. After PCR 
amplification, the libraries for each sample were pooled at equal EBV genomic copy 
quantities. Pooled libraries were hybridized with custom design EBV sequence 
specific biotinylated RNA baits, produced by Mycroarray Inc. Hybridized DNA 
libraries were captured with streptavidin beads and purified for final PCR 
amplification using Kapa HiFi polymerase. During the sequencing library 
preparation, we checked DNA quality and fragment size distribution using 
Bioanalyzer Agilent 1000 kit. Final library qualities were confirmed with 
Bioanalyzer Agilent High Sensitivity DNA kit. Multiplexed DNA libraries were 
sequenced in multiple lanes of Illumina MiSeq/HiSeq2000/NextSeq 500 platform 
with 1x75bp, 2x100bp, and 2x150bp, respectively. Qualities of raw sequencing reads 
were assessed using FastQC (Andrews, n.d.). Pooled reads with unique sample 
barcode sequences were separated using Novobarcode (Novocraft Technologies, 
Malaysia). Residual Illumina adaptor sequences were trimmed using cutadapt 
(Martin, 2011). The overall capture efficiency was around 40%. This might be 
because of pooling many libraries. 
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4.6 Computational 
4.6.1 Genome Assembly 
Key points of a good genome assembly following re-sequencing are a good 
quality of DNA material, high base quality of sequencing reads, and uniform read 
coverage representation throughout the genome. Residual sequence tags or adapter 
sequences can easily interfere with assembly process and create false calls. Prior to 
de novo assembly of viral genomic sequences, we first aligned adaptor/tag cleaned 
reads to the human genome in order to prevent possible chimeric assemblies. In 
addition to base quality trimming starting from 3’-end of reads, we also observed 
that removing ultra-low complexity reads, which contain long homopolymer 
stretches possibly resulted from sequencing errors, would improve contig assembly. 
However, this should be applied with cautious since EBV genome might have such 
long homopolymer stretches naturally.  
Contigs were generated with de novo sequence assembly tool Velvet  (Zerbino 
and Birney 2008) with VelvetOptimiser  (Consortium and Others 2012) with Kmer 
search ranging from 21 to 149, depending on read length. We used the Kmer that 
maximized N50, which is defined as the length of the shortest contig among the set 
of contigs whose sum makes up to 50% of all contig lengths. After initial assembly, 
we put contigs in genomic order according to the reference genome using ABACAS 
and extended their lengths when possible with additional read supports using 
IMAGE from PAGIT (Post assembly genome improvement toolkit)  (Swain et al. 
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2012) (Swain et al., 2012). We further merged possibly overlapping regions in 
guidance with reference genomes using in-house scripts. By nature, Illumina short 
reads (50-250bp) fail to resolve long repetitive regions, and such regions create 
misassemblies. Therefore, we masked these regions to avoid possible errors. We 
then constructed the scaffolds out of contigs and aligned original sequencing reads 
back to these scaffolds separately for every sample. Read alignments back to 
assembled contigs allowed us to check the presence of alternative variants not 
represented in final assemblies. By considering the frequency of variant bases at 
each position, we incorporated the major variant nucleotide into final contigs in the 
case of multiple allele presences. As a result, this ensures that the assembled 
genomes are the representatives of major strains even if there is a mixture in the 
sample. 
We deposited all analysis pipeline and custom scripts to GitHub under a 
repository named “EBV_Assembly_Pipeline”: 
https://github.com/yasinkaymaz/EBV_Assembly_Pipeline.git 
EBV_SequenceAnalysisPipeline.sh: A bash script for pipelining and 
processing for EBV sequencing datasets. 
 
4.6.2 Estimation of Genome Assembly Error Rate. 
The polymerase used during whole genome amplification, Phi29, has an error 
rate around 1 in 106-107  (Esteban, Salas, and Blanco 1993). Although a polymerase 
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with this error rate is considered as high fidelity, the sequencing technique and 
assembly methods also contribute to misassignment of bases to the final result. 
Therefore, we designed a set of controlled experiments to investigate errors and 
estimate rates by comparing the same genomes sequenced using different 
amplification methods. One of the assessment was regarding the errors introduced 
during the whole genome amplification. For this purpose, we replicated 5 of the 
sequenced primary biopsy associated viral genome sequences with amplification 
and included both type 1 and type 2 strains as well as a known lab strain Raji. After 
data processing and assembly processes mentioned above, we compared genomes 
using multiple sequence alignment using Mafft  (Katoh and Standley 2013). Then, 
we calculated the different bases between each other throughout genomes by 
excluding repetitive regions of EBV. In average, we found that the substitution rate 
between the whole genome amplified genomes using GenomiPhi v2 and their un-
amplified counterparts was ~2.2E-05 (see Table 4.3). We also estimated the error 
rate associated with preamp step prior to sWGA as ~1.6E-04, roughly ten fold 
increased, compared to standard WGA. This was an expected outcome since we used 
a polymerase with relatively lower fidelity in the preamp reaction. 
  
122 
Table 4.3. Sequencing error rate estimations based on a number of substitutions 
between replicates. *Assemblies from Palser et al. 2015 
 
Replicate 1 Replicate 2 
Number of 
Substitutions 
Number of 
Perfect 
Matches 
Error Rate 
DNA1_wga_EBV_type1 DNA1_EBV_type1 1 140069 7.14E-06 
DNA2_wga_EBV_type2 DNA2_EBV_type2 4 142932 2.80E-05 
DNA3_wga_EBV_type2 DNA3_EBV_type2 1 142154 7.03E-06 
DNA4_wga_EBV_type1 DNA4_EBV_type1 5 141643 3.53E-05 
DNA5_wga_EBV_type1 DNA5_EBV_type1 5 141643 3.53E-05 
Daudi_CellLine Daudi_D100_Preamp-sWGA 21 133445 1.57E-04 
Raji_CellLine_longRead Raji_CellLine_shortRead 3 136363 2.20E-05 
Raji_CellLine_longRead Raji_GenomiPhi 3 136454 2.20E-05 
Raji_Rep1_Preamp-sWGA Raji_Rep2_Preamp-sWGA 22 134478 1.64E-04 
Raji_CellLine_longRead Raji Assembly* 5 136145 3.67E-05 
Daudi_CellLine Daudi Assembly* 0 132782 0 
 
 
 
 
  
123 
4.6.3 Detection of Nucleotide Variation and Mixed Infection 
Analysis 
With Illumina sequencing, haplotype phasing is limited to insert size which 
is the fragments of DNA sequenced (typically 300-400bp). Thus, informative 
haplotype calls are limited. However, individual variant bases can be precisely 
determined with a certain depth of coverage levels. Another essential component of 
variant detection is the presence of a reference genome. In the case of EBV, there 
are two existing reference genomes in NCBI database one for each subtype, 
NC_007605 and NC_009334, type 1 and type 2, respectively. Although, type 1 
reference genome is a chimeric version of two EBV strains, B95-8 and Raji, type 2 
reference is a complete with type stain from BL cell culture AG876  (Dolan et al. 
2006). Given that both of the reference sequences are stains existed in the wild, the 
variant bases detected by comparison to references can also be interpreted as 
distances between strains. 
In order to detect sequence variations between EBV genomes, we aligned 
reads against both reference genomes using bowtie2  (Langmead and Salzberg 
2012) and marked PCR duplicate reads. After base recalibration and indel 
realigning, we called single nucleotide variations using GATK  (McKenna et al. 
2010c) with all alignment files simultaneously. We then filtered low quality and 
likely false calls due to repetitive sequences. For positions more than five non-PCR 
duplicate reads, if the variant frequency was >=95%, we flagged them as 
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homogenous. If the variant frequency was between 20 and 94%, we considered it as 
heterogeneous loci  (Hin Kwok et al. 2012b), and ambiguous otherwise.  
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Table 4.4 Sequencing read statistics of BL cell line mixture libraries. 
Library ID 
Viral 
subtype 
Read 
Length Total Reads Note 
J10D90_Rep1_PCRsWGA Type1 300 496,533  
J10D90_Rep2_PCRsWGA Type1 300 230,979  
J25D75_Rep1_PCRsWGA Type1 300 529,976  
J25D75_Rep2_PCRsWGA Type1 300 337,495  
J50D50_Rep1_PCRsWGA Type2 300 920,063  
J50D50_Rep2_PCRsWGA Type2 300 774,291  
J75D25_Rep1_PCRsWGA Type2 300 1,303,011  
J75D25_Rep2_PCRsWGA Type2 300 820,828  
J90D10_Rep1_PCRsWGA Type2 300 840,718  
J90D10_Rep2_PCRsWGA Type2 300 275,819  
Daudi_CellLine Type1 300 114,210  
Daudi_D100_PCRsWGA Type1 300 375,883 R-Preamp-sWGA 
Jijoye_CellLine Type2 300 15,094  
Jijoye_J100_PCRsWGA Type2 300 917,470 R-Preamp-sWGA 
Namalwa_CellLine Type1 300 29,866  
Raji_CellLine_longRead Type1 300 16,399  
Raji_Rep1_PCRsWGA Type1 300 422,839 R-Preamp-sWGA 
Raji_Rep2_PCRsWGA Type1 300 1,250,938 R-Preamp-sWGA 
Raji_GenomiPhi Type1 150 1,277,696  
Raji_GenomiPhi+GC Type1 150 535,253  
Raji_CellLine_shortRead Type1 150 290,733  
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One of the purposes of determining the variant positions in the sequenced 
strains is the detection of possible mixed infections. Infections with multiple 
different strains can be determined by comparing variant frequencies throughout 
the genome. However, this relies on the assumption that these strains are divergent 
enough to be distinguished with a few genomic loci. In fact, EBV genomes are 
generally stable except LMP1 genic region and it is quite hard to determine mixed 
infections unless strains are from two different types. In order to determine the 
sensitivity of our sequencing method for capturing multiple types of EBV, we 
conducted a controlled mixture sequencing experiment. We used Jijoye and Daudi 
as the representative genomes of type 1 and type 2 strains. We gradually increased 
the presence of one strain starting from 0%, 10%, 25%, 75%, and 100% while the 
other strain is decreasing accordingly (see Table 4.4). After sequencing the mixture 
DNAs, we aligned non-redundant reads back to assembled genomes. Then, we 
called the variants using read pile-ups with Samtools. This showed the alternative 
variant frequencies. We then checked frequencies of minor alleles which are kept 
out in the assembly. Since the assembly represents only major variants, checking 
the alternative variants is necessary to estimate the level of mixed infection. In 
addition, we constructed a phylogenetic tree with the genomic assembly of mixture 
sequences. This distance tree demonstrates that mixture genomes are correctly 
clustered according to their designated mixture ratios. This also ensures that our 
sequencing and assembly method correctly handles clinical specimens with possibly 
multiple strains. 
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EBV_SequenceAnalysisPipeline_SNPAnalysis.sh: This script is for viral 
genomic variant detection and several related downstream analysis. It can be 
download from https://github.com/yasinkaymaz/EBV_Assembly_Pipeline.git. 
 
4.6.4 Phylogenetic Analysis 
To determine the molecular epidemiological relationship between our EBV 
isolates and other published complete or partial EBV genome sequences from NCBI, 
we constructed phylogenetic trees. The whole genome sequences and gene coding 
sequences of these strains were then aligned using the Mafft. Phylogenetic analysis 
on the multiple sequence alignments generated for the whole genome sequences and 
selected genomic regions were constructed with Molecular Evolutionary Genetic 
Analysis program version 6 (MEGA v6.0)  (Kumar, Stecher, and Tamura 2016). 
Trees have been built using the Neighbor-joining method and Jukes-Cantor 
substitution model, and as a measure of the robustness of each node, the bootstrap 
method with 1000 pseudo replicates was applied. 
 
4.6.5 Recombination Analysis 
Potential recombination events between divergent nucleotide sequences were 
explored using Recombination Detection Program (RDP v.4.35β) software  (D. P. 
Martin et al. 2015). RDP incorporates several published recombination detection 
methods in a single platform to detect potential recombination events and their 
origin from the group of accurately aligned DNA sequences. These methods include 
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RDP, GENECONV, Chimera, MaxChi, SiScan, BootScan, and 3Seq. In all cases, 
default parameters were applied with Bonferroni correction as multiple comparison 
corrections and only a P-value < 0.01 were considered as significant events. Only 
events predicted by more than four of the methods were considered as true 
recombinations. Recombination events were evaluated by determining possible 
break point locations as evidence of recombinations for every genome assembly. 
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Chapter V. EBV Genome Sequences and Diversity 
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5.1 Summary   
Complete genome sequence of Epstein Barr virus is now attainable directly 
from patient samples using targeted sequence enrichment methods combined with 
next generation sequencing. The goal of our study was to investigate viral genomes 
directly in primary clinical specimens collected from Kenyan children who are 
either diagnosed with eBL or at risk by living in the same malaria-endemic area. 
With this project we endeavor to reveal, first, whether there are particular 
substrains associated with the disease; second, whether the tumor cell associated 
virus is identical with the one circulating in the plasma. For these purposes, we 
sequenced EBV genomes from 41 primary eBL biopsies as well as 21 plasma EBV 
genomes from patients diagnosed with eBL in addition to 29 EBV genomes from 
healthy controls. 
Analysis of individual EBV genomes consisted of de novo assemblies contigs, 
variation and recombination detection followed by comparative phylogenetic tree 
constructions. We extended the current study by comparing our sequences to 
available genomes up to date to provide more insight into regional variations. As a 
result, we observed that tumor-associated virus is identical to the circulating 
plasma virus. This supports the idea that the primary source of plasma viral load is 
the apoptotic tumor cells releasing intracellular content. We discovered a viral 
genome from an eBL tumor with one large 20 kb deletion resulting in a loss of 
multiple virions and lytic phase proteins. We detected three new inter-typic hybrid 
genomes from eBL patients, and all of them carried type 1 EBNA2 gene while their 
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EBNA3 genes were more similar to type 2 subtype. Regarding the subtype 
frequencies, we observed 75% type 1 association with eBL patients, regardless of 
the sample source such as plasma or tumor. Interestingly, type 1 and type 2 
infection frequency among the healthy kids were at equal levels (50-50%). This 
resulted in a statistically significant association between type 1 virus and eBL cases 
as opposed to healthy controls (P=0.016, Chi-square test). Finally, our whole 
genome-based phylogenetic analysis revealed the high level of diversity even among 
African strains, and the major demarcation was correlated with the subtype 
classification.  
Overall, our preliminary findings suggest that high-throughput sequencing 
will provide the means to fully unravel the complexity of EBV population structure 
Worldwide and provide insight into the viral variation that may influence 
oncogenesis and outcomes in eBL and other EBV-associated diseases. 
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5.2 Introduction 
EBV infects more than 90% of world's population and its prevalence also 
geographically overlaps with various malignancies in different regions of the world  
(Lawrence S. Young and Rickinson 2004). EBV causes a high incidence of infectious 
mononucleosis in young adults of Western countries while the EBV-linked disease 
in Sub-Saharan Africa is endemic Burkitt Lymphoma, which is the most prevalent 
pediatric cancer, and it is nasopharyngeal carcinoma in some of the South Asian 
countries  (Crawford 2001). It has been recently shown that the malaria 
Plasmodium falciparum infection causes polyclonal expansion of B cells, likely 
through metabolism sub-product of hemoglobin (hemozoin)  (Torgbor et al. 2014b) or 
PfEMP1 antigen at the surface of infected red blood cells  (Simone et al. 2011). The 
chronic malaria infection increases the AID expression which eventually enhances 
the likelihood of chromosomal translocation and somatic mutations  (Robbiani et al. 
2015). As a result, high mutagenic activity in B cells might result in increased 
random mutations in viral genomes and play a role in emergence of divergent 
strains. 
The first publication of a type I EBV sequence from a long-term 
lymphoblastoid cell culture B95-8 was in 1982 along the first comprehensive viral 
transcriptome mapping has been done with this study  (Baer et al. 1984). The 
second genome sequenced was a strain from a Chinese NPC culture cell, GD1  (Zeng 
et al. 2005). The first and only type 2 EBV genome sequenced was AG876 originated 
from a Ghanaian eBL case, which is still used as a reference for type 2  (Dolan et al. 
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2006). Recent advancements in high-throughput technologies accelerated the 
studies for whole genome sequencing. Even though the next generation sequencing 
helped to sequence whole genomes much more quickly compared to Sanger 
sequencing, the viral genome copy ratio to human DNA was still a huge challenge 
with metagenomic sequencing approach. The sequencing yield for the virus is 
extremely low as 0.014% relative to human  (P. Liu et al. 2011). By increasing viral 
genome abundance through triggering lytic replication, commonly used culture 
strains, Akata (from a Japanese BL) and Mutu (from an African BL) have been 
sequenced  (Z. Lin et al. 2013). As a solution to this abundance problem, an 
amplicon-based whole genome sequencing with multiple PCR products tiling across 
the genome has been used to sequence EBV from a primary NPC tumor biopsy  (Hin 
Kwok et al. 2012a). However; the significant improvements were achieved by 
implementing the targeted capture techniques which selectively enriched the viral 
DNA from a mixture by sequence-specific hybridization  (Depledge et al. 2011). This 
allowed to efficiently study with clinical samples in a better resolution in addition to 
reducing the sequencing cost. The major advantage of these developments is that 
the disease-related clinical information can easily be associated with molecular 
features and interpreted in the context of the natural host-pathogen environment. 
This also opens new opportunities to utilize primary clinical specimens and 
prevents limited research with only long-term cell lines. As a result, several studies 
provided multiple complete or partial viral genomic sequences from nasopharyngeal 
carcinoma tumors, EBV-associated gastric and lung cancers. Similar studies 
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followed with BL tumors from Ghana, Brazil, and Argentina  (H. Kwok et al. 2014; 
Y. Liu et al. 2016; S. Wang et al. 2016; Lei et al. 2015). Palser et al. conducted the 
largest study examining viral genome diversity Worldwide which was led by 
Wellcome Trust Sanger Institute, UK  (Palser et al. 2015). This study revealed the 
first global EBV genome diversity and provided various genomes isolated from 
multiple tumors after establishing spontaneous lymphoblastoid cell lines (sLCL). 
Similar but smaller scale studies continued accumulating new genomes and proved 
more information about regional diversities  (Simbiri et al. 2015). Although, new 
study designs have started to emerge investigating the associations between 
diseases and viral genomic diversity, these genome-wide examinations in case-
control settings are still at very early stages  (Chiara et al. 2016). 
Here in this work, we attempted to conduct a genome-wide association study 
for the virus regarding eBL with a large case-control sample set from an endemic 
malaria area. Here, we test the hypothesis that a subset of EBV strains is 
associated significantly more frequently with eBL tumors, and viral genomes of 
healthy individuals from the same geographical location do not carry the same 
variant as frequent. For this purpose, we sequenced multiple primary clinical 
specimens from Kenyan children diagnosed with eBL and compared them to 
healthy control children from the same region. 
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5.3 Results 
5.3.1 Study Set Demographics and Sequencing Data Quality 
In this study, we sequenced EBV genomic DNA from various sources of 
primary clinical specimens. We sequenced viral genomes from 41 primary eBL 
tumors, 21 plasma of patients diagnosed with eBL, and 29 blood DNAs of healthy 
controls. In addition, we included EBV-positive BL culture genomes, Namalwa, 
Daudi, Jijoye, Raji, as well as viral genomes of newly established three eBL cell 
lines eBL_CL-1, eBL_CL-2, and eBL_CL-3. A total of 98 unique EBV libraries were 
sequenced with multiple sequencing lanes of Illumina. Table 5.1 summarizes the 
sample set included in this study. 
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Table 5.1 The distribution of sample sources included in the whole genome EBV 
sequencing set. 
 
DNA source N (%) 
Primary eBL Tumor 41 (41.8%) 
Plasma DNA from eBL patients 21 (21.4%) 
Blood DNA from healthy control kids 29 (29.6%) 
New eBL cell lines 3 (3%) 
Commonly used BL cell lines 4 (4%) 
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We isolated the DNA from clinical specimens and prepared sequencing 
libraries followed by viral genome enrichment. We amplified whole genome DNAs of 
some of these when necessary by following the methods explained in Chapter IV. 
We included a group of individuals as healthy controls with a certain level of viral 
loads (>1 EBV copy/ng blood DNA). Since the total viral copies in cell pellet DNA 
isolates from these healthy controls were not enough to directly sequence, we 
preprocess the DNA using the preamp-sWGA method we developed (explained in 
Chapter IV). We matched the age and geography of the control individuals with 
children diagnosed with eBL (case group) by collecting blood DNA from healthy 
children who lived in the same malaria endemic region. These kids did not 
demonstrate symptoms of any lymphoma before the time of collection, but they were 
possibly exposed to malaria multiple times. 
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Table 5.2 Samples in the sequencing set and their processing information in 
addition to basic sequencing statistics. 
Sample ID Preprocessing 
Viral 
subtype SampleSource 
Read 
Length Total Seq reads 
eBL_CL-01 Direct Sequencing Type1 New BL_CellLineDNA 300 27,728 
eBL_CL-02 Direct Sequencing Type2 New BL_CellLineDNA 300 37,293 
eBL_CL-03 Direct Sequencing Type1 New BL_CellLineDNA 300 130,447 
Daudi Direct Sequencing Type1 BL_CellLineDNA 300 114,210 
Jijoye Direct Sequencing Type2 BL_CellLineDNA 300 15,094 
Namalwa Direct Sequencing Type1 BL_CellLineDNA 300 29,866 
Raji Direct Sequencing Type1 BL_CellLineDNA 300 16,399 
HC-0001 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 1,989,031 
HC-0002 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 2,573,344 
HC-0003 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 3,256,865 
HC-0004 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 6,191,128 
HC-0005 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 2,230,574 
HC-0006 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 14,005,054 
HC-0007 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 13,554,411 
HC-0008 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 4,038,485 
HC-0009 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 5,264,476 
HC-0010 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 5,080,095 
HC-0011 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 2,361,855 
HC-0012 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 4,609,922 
HC-0013 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 399,047 
HC-0014 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 1,373,086 
HC-0015 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 3,517,550 
HC-0016 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 5,312,268 
HC-0017 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 1,194,255 
HC-0018 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 3,443,411 
HC-0019 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 1,401,820 
HC-0020 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 3,297,486 
HC-0021 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 1,691,945 
HC-0022 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 986,623 
HC-0023 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 149,295 
HC-0024 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 1,248,198 
HC-0025 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 1,179,837 
HC-0026 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 555,072 
HC-0027 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 457,153 
HC-0028 Preamp-sWGA Type2 BloodDNA_fromHealthyKid 300 1,910,804 
HC-0029 Preamp-sWGA Type1 BloodDNA_fromHealthyKid 300 8,132,282 
eBL-Tumor-0001 GenomiPhi-WGA Type1 eBL_primaryTumorDNA 200/300 4,222,227 
eBL-Tumor-0002 GenomiPhi-WGA Type1 eBL_primaryTumorDNA 200/300 6,479,721 
eBL-Tumor-0003 GenomiPhi-WGA Type2 eBL_primaryTumorDNA 200/300 8,625,903 
eBL-Tumor-0004 Preamp-sWGA Type1 eBL_primaryTumorDNA 300 1,123,872 
eBL-Tumor-0005 GenomiPhi-WGA Type1 eBL_primaryTumorDNA 200/300 4,648,123 
eBL-Tumor-0006 GenomiPhi-WGA Type1 eBL_primaryTumorDNA 200/300 6,448,397 
eBL-Tumor-0007 GenomiPhi-WGA Type1 eBL_primaryTumorDNA 200/300 5,448,856 
eBL-Tumor-0008 Preamp-sWGA Type2 eBL_primaryTumorDNA 300 10,438,253 
eBL-Tumor-0009 Preamp-sWGA Type1 eBL_primaryTumorDNA 300 926,150 
eBL-Tumor-0010 Preamp-sWGA Type1 eBL_primaryTumorDNA 300 21,509,972 
eBL-Tumor-0011 GenomiPhi-WGA Type1 eBL_primaryTumorDNA 200/300 14,949,732 
eBL-Tumor-0012 GenomiPhi-WGA Type2 eBL_primaryTumorDNA 200/300 3,673,227 
eBL-Tumor-0013 GenomiPhi-WGA Type1 eBL_primaryTumorDNA 200/300 7,861,933 
eBL-Tumor-0014 GenomiPhi-WGA Type1 eBL_primaryTumorDNA 200/300 8,701,944 
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eBL-Tumor-0015 GenomiPhi-WGA Type1 eBL_primaryTumorDNA 200/300 5,825,147 
eBL-Tumor-0016 GenomiPhi-WGA Type1 eBL_primaryTumorDNA 200/300 1,161,216 
eBL-Tumor-0017 Direct Sequencing Type2 eBL_primaryTumorDNA 200 10,699,217 
eBL-Tumor-0018 Direct Sequencing Type1 eBL_primaryTumorDNA 200 11,258,545 
eBL-Tumor-0019 Direct Sequencing Type1 eBL_primaryTumorDNA 200 16,192,472 
eBL-Tumor-0020 Direct Sequencing Type2 eBL_primaryTumorDNA 200 14,633,495 
eBL-Tumor-0021 Direct Sequencing Type1 eBL_primaryTumorDNA 200 14,430,586 
eBL-Tumor-0022 Direct Sequencing Type1 eBL_primaryTumorDNA 200 7,687,200 
eBL-Tumor-0023 Direct Sequencing Type1 eBL_primaryTumorDNA 200 4,481,944 
eBL-Tumor-0024 Direct Sequencing Type2 eBL_primaryTumorDNA 200 2,585,251 
eBL-Tumor-0025 Direct Sequencing Type1 eBL_primaryTumorDNA 200 9,775,107 
eBL-Tumor-0026 Direct Sequencing Type2 eBL_primaryTumorDNA 200 4,070,074 
eBL-Tumor-0027 Direct Sequencing Type1 eBL_primaryTumorDNA 200 2,473,450 
eBL-Tumor-0028 Direct Sequencing Type2 eBL_primaryTumorDNA 200 2,785,996 
eBL-Tumor-0029 Direct Sequencing Type1 eBL_primaryTumorDNA 200 7,602,074 
eBL-Tumor-0030 Direct Sequencing Type1 eBL_primaryTumorDNA 200 6,079,669 
eBL-Tumor-0031 Direct Sequencing Type1 eBL_primaryTumorDNA 200 3,972,963 
eBL-Tumor-0032 Direct Sequencing Type1 eBL_primaryTumorDNA 200 7,118,274 
eBL-Tumor-0033 Direct Sequencing Type2 eBL_primaryTumorDNA 200 18,395,334 
eBL-Tumor-0034 Direct Sequencing Type1 eBL_primaryTumorDNA 200 5,679,398 
eBL-Tumor-0035 GenomiPhi-WGA Type2 eBL_primaryTumorDNA 200/300 6,133,367 
eBL-Tumor-0036 Preamp-sWGA Type2 eBL_primaryTumorDNA 300 1,873,678 
eBL-Tumor-0037 Direct Sequencing Type1 eBL_primaryTumorDNA 200 4,781,768 
eBL-Tumor-0038 Direct Sequencing Type1 eBL_primaryTumorDNA 200 1,652,556 
eBL-Tumor-0039 Direct Sequencing Type1 eBL_primaryTumorDNA 200 3,484,138 
eBL-Tumor-0040 Direct Sequencing Type2 eBL_primaryTumorDNA 200 3,758,609 
eBL-Tumor-0041 Direct Sequencing Type1 eBL_primaryTumorDNA 200 6,158,191 
eBL-Plasma-0035 Preamp-sWGA Type2 PlasmaDNA_fromBLpatient 300 385,303 
eBL-Plasma-0036 Preamp-sWGA Type2 PlasmaDNA_fromBLpatient 300 727,755 
eBL-Plasma-0037 Preamp-sWGA Type1 PlasmaDNA_fromBLpatient 300 52,615,528 
eBL-Plasma-0038 Preamp-sWGA Type1 PlasmaDNA_fromBLpatient 300 2,982,299 
eBL-Plasma-0039 Preamp-sWGA Type1 PlasmaDNA_fromBLpatient 300 2,834,853 
eBL-Plasma-0040 Preamp-sWGA Type2 PlasmaDNA_fromBLpatient 300 336,725 
eBL-Plasma-0041 Preamp-sWGA Type1 PlasmaDNA_fromBLpatient 300 1,055,728 
eBL-Plasma-0042 Preamp-sWGA Type1 PlasmaDNA_fromBLpatient 300 1,226,736 
eBL-Plasma-0043 Preamp-sWGA Type2 PlasmaDNA_fromBLpatient 300 643,566 
eBL-Plasma-0044 Preamp-sWGA Type1 PlasmaDNA_fromBLpatient 300 992,336 
eBL-Plasma-0045 Preamp-sWGA Type1 PlasmaDNA_fromBLpatient 300 9,600,176 
eBL-Plasma-0046 Preamp-sWGA Type1 PlasmaDNA_fromBLpatient 300 7,416,764 
eBL-Plasma-0047 Direct Sequencing Type1 PlasmaDNA_fromBLpatient 300 2,209,552 
eBL-Plasma-0048 Direct Sequencing Type2 PlasmaDNA_fromBLpatient 300 117,683 
eBL-Plasma-0049 Direct Sequencing Type2 PlasmaDNA_fromBLpatient 300 352,588 
eBL-Plasma-0050 Direct Sequencing Type1 PlasmaDNA_fromBLpatient 300 528,192 
eBL-Plasma-0051 Direct Sequencing Type1 PlasmaDNA_fromBLpatient 300 6,039,246 
eBL-Plasma-0052 Preamp-sWGA Type1 PlasmaDNA_fromBLpatient 300 1,682,856 
eBL-Plasma-0053 Preamp-sWGA Type1 PlasmaDNA_fromBLpatient 300 9,207,274 
eBL-Plasma-0054 Direct Sequencing Type2 PlasmaDNA_fromBLpatient 300 1,063,382 
eBL-Plasma-0055 Direct Sequencing Type1 PlasmaDNA_fromBLpatient 300 1,514,583 
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Figure 5.1 Genome coverage view of sequenced samples after De Novo assembly. 
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Following the sequencing with multiple lanes of Illumina, we de novo 
assembled the genomes. Table 5.2 summarizes preprocessing information and 
sequencing statistics for each library. Analysis of individual EBV genomes consisted 
of de novo assemblies of genomes, variation detection followed by comparative 
phylogenetic tree constructions. Figure 5.1 shows a representative genome-wide 
plot for the covered genomic regions after de novo assembly of a subset of samples. 
We extended the current study by comparing our sequences to publicly available 
genomes up to date to provide more insight into regional variations. Finally, we 
conducted an association test between the viral genome types and disease cases 
with a case-control design. 
 
5.3.2 Genomic Comparison of Plasma EBV and Tumor EBV from 
patients 
Circulating cell-free (CCF) DNA is defined as intact or mostly fragmented 
DNA found in the circulatory systems. The level of CCF EBV DNA in healthy 
carriers is often below the detection limits while it reaches to maximum levels when 
the person is diagnosed with EBV-associated carcinoma or lymphoma. For Burkitt 
patients, it has been shown that plasma EBV DNA levels and blood cellular fraction 
EBV levels were significantly correlated  (Mulama et al. 2014). The source of CCF 
EBV also referred as plasma EBV DNA, while is not precisely known, can be tissue 
injury, pregnancy, or neoplasia. However, tumor cells are the usual suspect in 
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cancer patients, and apoptotic or necrotic cells release cell-free DNA. Several 
studies showed that the plasma EBV DNA levels positively correlate with tumor 
burden and stage of NPC patients and removal of tumors led dramatic decrease in 
plasma EBV levels  (J.-C. Lin et al. 2004; Ma et al. 2006; Chan et al. 2005). This 
indicates that the source of plasma EBV DNA is majorly tumor cells. Besides, 
studies showed that CCF EBV DNA is mostly naked rather than being protected by 
encapsidation using DNase treatment assays  (Ryan et al. 2004).  
Although the importance of plasma EBV levels of NPC patients has been 
boldly emphasized, the prognostic value for Burkitt lymphoma remains unexplored. 
Knowing that the plasma viral DNA and tumor-associated virus are same, at least 
same genome subtype, would open new avenues for utilizing plasma based 
prognostic approaches. Our initial question regarding the plasma viral genomes was 
whether they were identical genomes with the tumor virus or not.  
To answer this question, we sequenced seven eBL primary tumor virus 
genomes as well as their matching plasma associated virus DNAs. Following the 
sequencing and assemblies, we compared the pairs by multiple sequence alignment 
and looked at the differences between genomes. The phylogenetic tree demonstrates 
that almost all of plasma viral isolates are same as their tumor counterparts. This 
entirely agrees with the hypothesis that the primary source of plasma viral DNA is 
the apoptotic tumor cells which release cell-free DNA into the circulating blood 
stream. Only one of the plasma virus from the pairs showed slight differences from 
its tumor counterpart which suggest that there might be a secondary infection 
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unique to that particular patient. Nevertheless, both of the viral isolates were the 
same subtype, type 1 EBV. This putative secondary infection case requires further 
validation with an alternative technique. In addition to 7 plasma-tumor pair viral 
genome sequences, we extended this investigation by genome-typing eight more 
patients using conventional PCR. Table 5.3 shows that all of these tumor-plasma 
virus pairs also belong to matching virus subtypes. Overall, these findings strongly 
support the idea that plasma virus mainly originates from tumor cells.  
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Table 5.3. EBV genome types found in tumor-plasma pairs using PCR in addition 
to whole genome sequenced samples. Out of 8 randomly selected patients, all types 
were found to be same in plasmas and their tumor pairs. 
 
Patient Tumor DNA Plasma DNA 
eBL Patient 1 Type 1 Type 1 
eBL Patient 2 Type 2 Type 2 
eBL Patient 3 Type 2 Type 2 
eBL Patient 4 Type 1 Type 1 
eBL Patient 5 Type 1 Type 1 
eBL Patient 6 Type 1 Type 1 
eBL Patient 7 Type 1 Type 1 
eBL Patient 8 Type 1 Type 1 
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5.3.3 Diversity and Phylogenetic analysis of EBV genomes 
Worldwide 
We compared genomes in our sequencing set by constructing a phylogenetic 
tree following a multiple sequence alignment. We masked repetitive regions 
according to the reference genome. Pairwise distance calculations were based on 
Jukes-Cantor nucleotide substitution model, and the tree was constructed with the 
simple Neighbor-Joining method. Figure 5.2 demonstrates the tree with all of the 
genomes in our sequencing set. The major demarcation is the separation of isolates 
based on their genomic subtypes, type 1 and type 2, regardless of their source. 
Although viral genomes, especially type 2, which were isolated from healthy 
children’s blood tend to accumulate as subclusters, generally there is no clear sub-
branching unique to healthy controls. Proper clustering of plasma tumor pair 
isolates can also be seen in this larger tree. The whole genome analysis also showed 
the segregation of EBV type 2 strains into two highly supported distinct clusters. 
Overall, this comparative whole genome analysis demonstrates the level of diversity 
in a relatively small geographic area, and yet it is hyperendemic regarding the 
malaria intensity.  
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Figure 5.2 A) Phylogenetic tree of whole EBV genomes in our sequencing set. Our 
sequencing set consists of 62 genomes from eBL patients, 29 genomes from healthy 
children, and cultured cells strain for sequencing control. EBV genomes from 
healthy kids are represented with green squares, primary eBL tumors with red 
circles, plasma EBV from eBL kids are pink circles, BL culture EBVs are yellow 
triangles, Type 1 reference genome (NC_007605) is red diamond, Type2 reference 
genome (NC_009334) is a blue diamond. Three new established BL culture EBV 
genomes are represented by brown triangles. Red color branches represent type 1 
genomes, while type 2 is with blue branch color. B) Same tree in traditional view. 
The evolutionary history was inferred using the Neighbor-Joining method  (Saitou 
and Nei 1987). The optimal tree with the sum of branch length = 0.07924741 is 
shown. The tree is drawn to scale, with branch lengths in the same units as those of 
the evolutionary distances used to infer the phylogenetic tree. The evolutionary 
distances were computed using the Jukes-Cantor method  (Jukes, Cantor, and 
Others 1969) and are in the units of the number of base substitutions per site. All 
positions with less than 95% site coverage were eliminated. That is, fewer than 5% 
alignment gaps, missing data, and ambiguous bases were allowed at any position. 
There was a total of 128380 positions in the final dataset. Evolutionary analyses 
were conducted in MEGA6  (Tamura et al. 2013). 
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To be able to estimate the effect of malaria on viral genome divergence, we 
further compared genomes in our sequencing set to publicly available strains 
collected from various countries all around the world. We added more than 120 
genomes and constructed the tree again (Figure 5.3 - A). This tree of whole EBV 
genomes includes various tumor isolates such as BL, NPC, and EBVaGC, cell 
cultures, as well as sLCL EBV genomes from healthy individuals in addition to our 
direct isolates. The tree demonstrates the apparent divergence of genomes based on 
type as well as geographical locations. As previously observed, we show evidence for 
closely related phylogeny being found among sequences derived from different 
geographic regions  (Palser et al. 2015). Figure 5.3 - B demonstrates the divergence 
based on whole genomes again after masking major type specific genes EBNA2 and 
EBNAs.  
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Figure 5.3 A) Phylogenetic tree of 226 complete genome sequences. Viral genomes 
in this tree are color coded based on their subtypes as type 1 genomes are 
represented by red circles while blue represents type 2. Yellow circles are used to 
label inter-typic hybrid genomes. B) A Same tree without EBNA2/EBNA3s regions. 
The evolutionary history was inferred using the Neighbor-Joining method  (Saitou 
and Nei 1987). The optimal tree with the sum of branch length = 0.20057488 is 
shown. The tree is drawn to scale, with branch lengths in the same units as those of 
the evolutionary distances used to infer the phylogenetic tree. The evolutionary 
distances were computed using the Jukes-Cantor method  (Jukes, Cantor, and 
Others 1969) and are in the units of the number of base substitutions per site. All 
positions with less than 95% site coverage were eliminated. That is, fewer than 5% 
alignment gaps, missing data, and ambiguous bases were allowed at any position. 
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There was a total of 107023 positions in the final dataset. Evolutionary analyses 
were conducted in MEGA6  (Tamura et al. 2013).  
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5.3.4 Novel Intertypic Hybrid Genomes  
The first demonstration of a recombination between two types of EBV in the 
lab involved conducting a superinfection experiment with both types  (Skare et al. 
1985). The reports of naturally occurring recombinant viral genomes followed  
(Burrows et al. 1996; Yao, Tierney, Croom-Carter, Cooper, et al. 1996), and many 
more evidence have been provided for recombination events occurring between 
types of EBV. Thus, the continuance of type 1 and type 2 properties irrespective of 
the recombinations should be considered in clinical concepts. Although, it is hard to 
estimate the frequencies of recombinant genomes unless assays include all EBNA 
genes simultaneously, the observations from these individual studies emphasize on 
the underestimated functional importance of type 2 genomes in diseases. Intertypic 
recombinant virus genomes can be found in various cancer patients  (Cho and Lee 
2000) and lymphoma cells  (Aguirre and Robertson 1999). These intertype viruses 
are replication competent and are still able to successfully transform cells to 
generate spontaneous LCLs  (Kim, Kang, and Lee 2006). This supports the 
importance of EBNA2 gene of type 1 in efficiently transforming B cells compared to 
type 2 strains given intertypic recombinant virus genomes almost always contain 
type 1 EBNA2 and type 2 EBNA3s genes.  
Recombinant genomes might be products of relatively recent events because 
the diversity of EBNA1 and LMP1 does not correlate with types and these regions 
still carry their geographic divergence patterns  (Midgley et al. 2000). As an 
interpretation of this, one can infer that each geographic area has its unique hybrid 
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genome as a result of more frequent recombination events. However, the necessity 
of both types to be present in the same cell at the same time via superinfection is 
the major limitation for the frequent occurrence of hybrid genomes. One of the 
suggested hypothesis for the mysterious emergence of EBV subtypes is that during 
human evolutionary history two human populations carrying same ancestor virus 
got separated from each other. The virus with them diverged into two distinct 
genomes at certain EBNA genes. Then, these two human populations converged 
again setting the stage for new recombination events between divergent subtypes  
(McGeoch and Gatherer 2007). 
The biological question is whether these incidents are products of an early 
ancestral event or they occur more frequently as the different strains find a chance 
to recombine in a cell. To help to answer this question, we further investigated the 
genome isolates to determine whether there are any recombinant genomes. For this 
purpose, we compared the pairwise similarities of each genome against both type 1 
and type 2 reference genomes. By applying a tiling window through the whole 
genome, we were able to determine which parts are more similar to any of the 
subtypes. As a result, we discovered three new hybrid EBV genomes which carry 
type 1 EBNA2 gene while their EBNA3 genes are more similar to type 2 subtype. 
Figure 5.4 demonstrates genome-wide similarity tracks for each hybrid against 
both reference genomes. Also, we also included one previously known recombinant 
isolate from Palser et al. as a control for our detection approach. Two of these new 
hybrids were isolated from primary eBL tumors while the third was from a plasma 
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again from a patient diagnosed with eBL. While each of these was from separate 
individuals, we did not observe any chimeric genomes isolated from healthy 
controls. However, the occurrence rate as 3 in 62 eBL isolates suggest that we 
might have missed the chance to capture one such genome with only sample size 29 
healthy controls. This shows that it is hard to attribute significance to this event 
and to associate with the disease.  
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Figure 5.4. Similarity plots for identifying inter-typic hybrid genomes. Breakpoint 
distribution plot. These incidents in the genome sequences were supported by 
statistical evidence for the putative recombination breakpoints, and only 
breakpoints detected by all four algorithms were considered (RDP, BOOTSCAN, 
Chimaera, Sister-Scanning analysis). 
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5.3.5 Viral Genomic Variants and Associations with eBL 
It has been suggested that the main driving force behind the sequence 
divergence among the viral genomes was HLA class II types of infected individuals. 
Since major HLA types significantly differ between different ethnic groups at 
various geographic locations, this also reflected viral genome variations  (Tzellos 
and Farrell 2012). In addition to finding EBNA2 to be the key determinant of 
differential lymphocyte transformation efficiency  (Cohen et al. 1989b; Lucchesi et 
al. 2008), LMP1 gene was also found to be essential for lymphocyte growth 
transformation  (Kaye, Izumi, and Kieff 1993). Recently, EBNA3B has been 
determined to be playing a tumor suppressor role in lymphomagenesis  (White et al. 
2012). These findings ensure that genomic sequence variants of viral strains might 
lead to distinct outcomes of cell fate. In general, EBV sequence and disease 
association studies examined several cases and control sets for viral sequence and 
type differences between patient and healthy groups. The most commonly targeted 
viral genomic regions for their variants for association studies are EBNA genes 
(mainly for subtyping), other genes such as LMP1, and BZLF1 gene (different lytic 
replication) (reviewed in  (Chang et al. 2009)). However, these studies fail to draw 
definitive conclusions regarding associations between diseases and any viral 
genomic variants including the subtypes type 1 and type 2. Although there is no 
clear significant association between these variants and diseases, these variants 
might differ in functions to induce several host signaling pathways. These studies 
were limited to only one or two viral gene sequences. In addition, there is no such 
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association study examining differences between the virus in BL tumors and 
isolates from healthy individuals except one study focusing on LMP1 gene only  
(Wohlford et al. 2013). Other disease association studies also lack proper random 
sampling of individuals from same geographic and environmental conditions. We 
address these important factors in our design carefully by sequencing the whole 
genome of the virus instead of targeting certain regions and choosing patient and 
healthy controls from the same geographic area under the same malaria 
endemicity. 
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Figure 5.5 Coverage and variants histogram with the circos plot.  
  
161 
Previously, it has been reported that BL cell lines P3HR1 and Daudi have 
deleted regions spanning nuclear protein-coding EBNA2 gene  (Kelly, Bell, and 
Rickinson 2002b). Additionally, loss of regions that encode for miRNA sequences in 
B95-8 and loss of EBNA3C in Raji strains have also been reported  (B. D. Parker et 
al. 1990; Polack et al. 1984). We could not detect deletion of the mentioned genes in 
our isolates, however; one of the genomes in eBL tumors carries a large deletion 
between roughly 100kb and 120kb region spanning multiple virions related and 
lytic phase genes, such as BBRF1/2, BBLF1/3, BGLF1/2/3/4/5, and BDLF2/3/4 (see 
Figure 5.5). This circos plot also shows SNV distributions through the genome 
separate for type 1 and type 2. Highly divergent regions are EBNA3 genes and 
LMP1 gene. 
We compare genomic sequences of viral DNA from eBL patients to viral 
genomes of 29 healthy kids from the same malaria endemic region with an age-
geography matched case-control set. Our initial association test was regarding the 
genome subtype of the virus. To determine the type of the genomes, for each sample 
we compared the number of single nucleotide variations, against each reference 
genome, within EBNA2, EBNA3A-B-C genes. We also complemented this analysis 
by comparing overall sequencing read alignment rates of each sample genome 
against both references.  
We first intended to assure that our sampling or inclusion criteria is 
completely random and does not depend on any factor. Since we relied on viral load 
levels of clinical specimens to prepare sequencing libraries, we checked to determine 
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if there is any bias towards one of the types concerning viral load levels. Figure 5.6 
- A shows the nonsignificant relationship between viral loads and viral genome 
types. This indicates that our sample inclusion criteria were not biased regarding 
the uniform sampling all viral subtypes. We also aimed to verify that the plasma 
virus is representative of the tumors from the patients and they can be included in 
the association test. As we demonstrated above, plasma viral types always matched 
with the tumor viral type from the same patients. In addition, the viral type 
frequencies in plasma samples from independent patients were entirely equivalent 
to type frequencies in BL tumors (see Figure 5.6 - B). 
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Figure 5.6 A) There is no significant relationship between viral genome type and 
viral load levels (P=0.126, t-test). This shows that our sampling method is not 
biased and skewed towards one of the genomes. B) Type 1 and Type 2 infection 
frequencies among the Kenyan children in malaria holoendemic region comparing 
eBL patients to healthy kids. The observed frequency of EBV types among healthy 
kids is 50-50% while it is skewed in favor of type 1 (75%) among eBL kids.  
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To be precise in our calculations, we excluded the three inter-typic hybrid 
genomes from this analysis as well as the plasma virus genomes paired with the 
tumor from same patients. As a result, we determined that the 74.5% of total 55 BL 
cases carried type 1 virus while only 25.5% carried type 2 infection. On the other 
hand, we found that the type 1 carrying healthy controls were at similar levels as 
type 2 carrying healthy children, 48.2% vs. 51.7%, respectively. This striking viral 
type frequency difference between BL cases and healthy controls is statistically 
significant with p=0.01605 and Chi-square statistics 5.79 (Table 5.4). To our 
knowledge, this is the first time to demonstrate the equal type frequencies in 
healthy carriers while type 1 is the predominant type in BL patients in Africa 
malaria hyper endemic region. 
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Table 5.4. Contingency table used for testing the significance of the association 
between EBV genome type and BL. Chi-square p-value is significant at 0.05 
significance level, and the test statistics is 5.76.  
 
 BL Healthy Controls Marginal Row Totals 
Type 1 EBV 41 (74.5%) 14 (48.2%) 55 
Type 2 EBV 14 (25.5%) 15 (51.7%) 29 
Marginal Column 
Totals 55 29 84 (Grand Total) 
The chi-square statistic is 5.7968. The p-value is 0.016056.  
Count (% of marginal column totals) 
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5.4 Discussion 
EBV is the first virus found within a tumor cell over 50 years ago. However, 
we are just starting to decipher its possible role in pathogenesis. Sequencing 
technologies help to answer questions regarding the host-pathogen interactions by 
diving into the principal source, DNA. Here in this study, our goal was to identify 
EBV genome sequence variants and correlate these with endemic Burkitt 
lymphoma incidences. 
This study, for the first time, demonstrates by sequencing that circulating 
plasma virus of eBL patients are identical to their tumor virus. Although there were 
various attempts to utilize plasma virus as a biomarker in NPC patients, such 
studies were limited regarding the BL  (J.-C. Lin et al. 2004; Chan et al. 2005; Ma 
et al. 2006). Knowing that plasma virus is identical to the tumor-associated virus, 
this can be utilized in various ways such as tumor diagnosis, treatment monitoring, 
or tumor evolution studies. Circulating cell-free viral DNA can be monitored over 
time and examined as a factor affecting survival outcome of the patient. Combining 
with the recent applications of monitoring plasma EBV of eBL patients, sequencing 
virus genomes in clinical settings can be used in a predictive model for foreseeing 
relapses  (Westmoreland et al. 2017). 
The first large-scale attempt to demonstrate the broad diversity among 
Worldwide strains was by Palser et al. This study proves that geography plays a 
significant role in viral variation and needs to be properly accounted for in 
comparative studies. However, our sequencing approach is fundamentally different 
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than the one used in this study because we tried to avoid generating lab-cultured 
strains for enrichment via spontaneous lymphoblastoid cell lines. Directly 
sequencing the virus within the primary sources takes the snapshot of the 
population diversity unlike bottlenecking for replication competent strains with 
sLCL generation. Thus, the contribution of choosing the right sequence enrichment 
method is undeniable for capturing the real subtype frequencies. As a result, we 
discovered the dramatic difference between type 1 and type 2 infection rate in eBL 
patients compared to healthy control kids. By relying on the earliest genome typing 
studies, it is widely believed that the type 2 subtype is more prevalent in Africa 
compared to the rest of the World  (L. S. Young et al. 1987a; Apolloni and Sculley 
1994). However, there were reports also showing the contrary results and 
suggesting that type 2 might not be limited to Africa  (Sixbey et al. 1989). Besides 
all of this controversy, the fundamental reasons for the existence of two types 
require more investigations.  
Although it is hard, almost impossible, to infer linear ancestry from the 
phylogenetic tree because of possible extensive recombination levels, our 
comparative analysis demonstrated the level of diversity even in smaller 
geographies. Both of the parent strains have to be present within the same cell in 
order to recombine and give birth to a third strain. The likelihood of this event to 
happen would vary depending on the geographic area. The equivalent levels of both 
subtypes among healthy children might explain observing inter-typic hybrid 
genomes frequently in the same region. However, whether these genomes are 
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products of early ancestral events or often occur more frequently is not known. 
Interestingly, all hybrid genomes carried same recombination pattern which had 
the same EBNA2 and EBNA3s combinations. This entirely agrees with previous 
functional experiments demonstrating that EBNA2 gene is the key transformative 
factor in creating lymphoblastoid cell lines and EBNA3B playing a tumor 
suppressor role in lymphomagenesis  (White et al. 2012; Lucchesi et al. 2008). What 
kind of other functional advantages, such as better expanding host range or 
increasing virulence, a recombination gives to the virus needs further investigations 
in the light of hybrid genomes. On the other hand, finding hybrid viral genomes 
only in eBL patients does not indicate that these are unique to the disease because 
it is likely to capture such genomes among healthy controls with higher sample 
sizes.  
Finally, we detected a virus in an eBL tumor with a substantially large 
deletion causing a loss of various lytic and late genes. Increasing the examples of 
such incidences with more sequencing might help to understand the actual role of 
EBV in pathogenesis. As a conclusion, whole genome sequence differences between 
type 1 and type 2 EBV need to be investigated comprehensively with larger cohorts 
in order to pinpoint this fundamental divergence. Such investigation will not only 
decipher the puzzling pathogenic differences but also will help to understand how 
these two EBV types persist in the population at the same time. 
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Chapter VI. Conclusions 
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General Conclusions and Future Directions 
 In this research, we examined the expression and mutational spectrum vis-a-
vis clinical and molecular features of Kenyan children diagnosed with eBL and 
compared to publicly available data for sBL. We observed relative homogeneity of 
expression within tumors collected from our patient population suggesting no overt 
subtypes within eBL. Our initial expectation regarding the gene expression was to 
determine clinical subtypes with distinct expression profiles. We found minimal 
differences between tumors presenting in the jaw or abdomen but observed 
differences in expression that correlated with survival, viral presence, and type of 
EBV. We tested the hypothesis that eBL tumor cells carry mutated genes different 
from sBL tumors. Our comparative analysis confirmed the frequently mutated gene 
sets in eBLs to be almost same as sBLs; however, mutation frequencies were 
significantly lower in eBLs. We also detected previously undescribed somatically 
mutated genes and showed that the BL mutational spectrum appears to most 
greatly differ based on the type of EBV infecting the tumor rather than the 
geographic origin of the patient. Furthermore, we found that tumors harboring EBV 
type 1 display a significantly different host mutational profile compared to BL 
tumors with EBV type 2 and without EBV. This distinct mutational frequency 
profiles of tumors with different viral subtypes perfectly inlines with the known fact 
regarding the transformation ability differences of viral subtypes. 
 We also found that the differences in tumor mutational spectrum were more 
striking when categorized by viral presence or absence rather than geographic 
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origin. This was also supported by stronger differences in expression profiles in 
critical pathways as well as involving likely downregulation of PTEN affecting the 
central pathway of PI3K-Akt signaling followed by mTORC1 activation. It has been 
previously shown that EBV can modulate mTOR pathway by LMP2A (Moody et al. 
2005). Given the limited viral gene expression in latency I, EBV could be interacting 
with major host regulators especially through viral miRNAs (H.-J. Yang et al. 2013) 
or by regulating cellular miRNAs expressions (Forte et al. 2012). It has been 
recently demonstrated that EBV microRNA Bart6-3p can inhibit PTEN translation 
(Cai et al. 2015). Even though this could be the mechanism by which the virus 
interferes with critical cellular pathways, the consequences of viral miRNA 
interactions with PTEN and whether translational inhibition or mRNA degradation 
in EBV-positive BL needs further clarification. Our data shows that the mRNA 
transcription of PTEN itself is not significantly differentially expressed between 
EBV-positive and negative BLs. However, Ambrosio et al. found that protein levels 
of PTEN are significantly lower in EBV-positive BLs compared to negatives  
(Ambrosio et al. 2014). This suggests a mechanism in which viral miRNAs interact 
with PTEN causing a translational inhibition. Combined, this suggests that the 
virus plays a key role in oncogenesis beyond the possible role in potentiating the 
translocation. However, further functional assays are needed in order to validate 
viral compensation for the less frequent ID3, TCF3 or CCND3 mutations found in 
EBV-positive eBL tumors. 
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 Third, we discovered new mutations occurring in genes previously not 
reported in other BL studies. While many of these additional genes are mutated at 
low frequencies (<10%), they support the key roles of previously identified pathways 
(e.g. BCL7A as another member of SWI/SNF). These genes also implicate DNA 
repair regarding oncogenesis where we identify three previously undescribed genes 
(MSH6, RAD50, and PRKDC) involved in double strand repair and nonhomologous 
end joining. 
 Fourth, we found that not only does tumor gene mutation rates and 
distribution vary based on the presence of EBV but that tumors have different 
patterns of mutation based on EBV type. We observed that BLs with type 2 has a 
significantly higher average number of mutated genes relative to type 1 and that 
this rate is on par with viral negative tumors. The only observed consistent 
mutational difference was a lower rate of mutations in ID3 and TCF3, which 
supports the idea that the virus may play a critical role regulating these pathways 
during oncogenesis by alternatively driving AKT/mTOR signaling. The overall lower 
mutational rates in BLs with type 1 virus, suggest that type 1 virus may be 
providing survival advantages in other ways. This is consistent with the known 
ability of type 1 virus to better transform peripheral B cells to create 
lymphoblastoid cell lines. Given that previous studies have not seen significant 
differences in viral types in tumors relative to population controls, this suggests 
that many of these driver mutations while offering relative advantages in tumor 
growth are not in and of themselves necessary regarding oncogenesis. Further 
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studies with greater number of tumors and population controls can help to better 
understand the distribution of EBV within the general population in contrast to 
their role in eBL pathogenesis. 
 Finally, we observed that the viral expression pattern is consistent with viral 
latency I, as we expected, where EBV is substantially quiescent and maintained 
with EBNA1 expression. However, increased detection of lytic gene expression was 
suggestive of poor prognosis. It has been argued that this observed expression 
pattern may primarily be due to various levels of lytic reactivation (Fujita et al. 
2004). Consistent with the previous reports (Arvey et al. 2015), our results 
demonstrated similar heterogeneous viral gene expression in BL suggesting that 
tumor cells could be targeted by antiviral immunotherapies. Dysfunctional T cell 
immunity has been reported for children diagnosed with eBL who were defective for 
EBNA1 specific IFN-gamma T cell responses (Moormann et al. 2009b). This defect 
putatively allows latency I tumors to escape from immune surveillance. 
Interestingly, we found that one-third of the eBL tumors which carried type 2 EBV 
genome had significantly suppressed immunoproteasome complex gene 
transcriptions compared to eBLs with type 1 EBV. One explanation for this novel 
observation could be that type 2 EBV more readily infects immunocompromised 
individuals. Baarle et al. reported an increased prevalence of type 2 EBV among 
HIV patients (van Baarle et al. 2000). However, a larger cohort of HIV patients 
showed that T-cell impairment does not sensitize individuals for type 2 EBV 
infections (Yao et al. 1998b). Thus, an alternate explanation is that type 2 EBV 
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directly interacts with host regulatory components in order to interfere with 
immunoproteasome complex formation. Reduced transcriptional expression of these 
genes in EBV type 2 eBL tumors implies a mechanism in which viral components 
(coding or non-coding) suppress JAK/STAT1 mediated transcription. This could be 
an additional mechanism by which type 2 EBV is able to escape from immune 
surveillance by preventing T-cell responses (Sijts et al. 2002). Since we did not 
observe any viral transcriptional pattern differences compared to type 1 genes, this 
phenomenon requires further investigation to confirm. 
 As a summary of our mutational investigation, we have illustrated the key 
pathways implicated in BL oncogenesis integrating our analytical results with 
current literature (Figure 2.5 C). This expanded view of BL oncogenesis more 
clearly defines a role for EBV. Driving proliferation through PTEN/PI3K/AKT and 
CCND3 pathways may be an essential step toward bypassing the lack of mutations 
in the TCF3/ID3/CCND3 axis that may include SWI/SNF interactions of 
SMARCA4 as well. MYC translocation provides the pivotal accelerant while the 
gain of function mutations in CCND3 strengthens the pressure. Although the 
mutated genes which function in B cell development and chromatin remodeling 
complexes might contribute to this signaling, our results regarding gene expression 
and pathway differences suggest a role for viral microRNAs which can inhibit 
PTEN function and cause activated BCR signaling via AKT. Other genes frequently 
mutated in BL play roles in distinct but relevant pathways such as DNA repair and 
focal adhesion. Overall, this combined model demonstrates pathogenic mechanistic 
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routes to tumorigenesis BL and introduces a defined role for EBV that warrants 
further interrogation. 
 Although RNAseq based expression profiling technique gives clues about 
viral genome subtypes in tumors, we pursued to extend the investigation further by 
sequencing the EBV genomes in primary eBL tumors and of infected Kenyan 
children. Our initial expectation regarding the circulating plasma virus and tumor 
virus of the same patients was that they both originate from the same source and, 
thus, carry the same genome. As a result of our comparative analysis, we concluded 
that plasma viral genomes of eBL kids are identical with their tumor viruses as we 
expected. This opens up new opportunities for cell-free circulating plasma DNA to 
be utilized as a diagnostic or a prognostic tool. Besides, knowing that eBL tumor 
cells carry the same virus in plasma, better association studies can be conducted 
with larger cohorts without waiting to reach enough tumor tissue samples. 
Secondly, we intended to measure the association frequencies of viral subtypes and 
eBL with a case control study. In the light of previous studies and literature, we 
expected to observe a similar subtype association rate even among healthy children 
control group. However, we found that infection rates of two EBV subtypes were at 
equal levels among healthy children. Strikingly, on the other hand, we determined a 
significant association between the type 1 EBV and eBL cases in a case-control 
study which involves virus genomes from healthy age-geography matched children. 
The significant difference between the frequencies of two subtypes suggests that 
children carrying type 1 infection have a higher likelihood of developing lymphoma. 
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In conjunction with our findings regarding the mutated host gene rate differences 
between type 1 carrying tumors and type 2 carrying tumors, it becomes more 
evident that the viral genome typing assays should be incorporated into clinical 
diagnostic assays to guide local pediatric oncologists in Kenya. 
 Distinct EBV strains might contribute to different diseases. To test this, one 
can compare viral genomes of NPC cases in East Africa to NPC-associated viruses 
from southern-China. This might shed light on some common viral sequence 
features shared by both cases. As a matter of fact, an association study that 
involves multiple virus-associated diseases worldwide can be much more 
informative. In such study, various geographic regions and proper healthy controls 
should be included. However, there are still many unanswered questions in the 
EBV research area; do viral genome variations contribute to the viral preferences 
for infecting epithelial cells or B cells? Why there are two types of EBV genomes is 
still an unexplored phenomenon. Both types should have functional properties 
which would allow them to persist in the population without getting wiped-out. Are 
the intertypic hybrid genomes the products of early ancestral events and should 
they be considered as the third subtype, or they occur more frequently than we can 
think? 
 In the near future, it is possible that researchers will sequence many more 
viral genomes to investigate disease associations and utilize sequence information 
for biomarker or vaccine development. The increasing sequence samples will require 
accurate handling with standardized bioinformatics analysis pipelines. Therefore, 
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an online public database storing all sequenced EBV genomes and their relevant 
clinical information would serve as a base for investigators in the process of 
hypothesis generation. 
 Here in this dissertation, we developed novel bioinformatic approaches and 
workflows to analyze and investigate expression profiles of tumors as well as viral 
genomic variations. We identified important differences based on viral content and 
clinical outcomes by genomic and mutational analyses of Burkitt lymphoma tumors. 
Overall, these suggested new avenues for the development of prognostic molecular 
biomarkers and therapeutic interventions. 
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APPENDIX 
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A. EBV Genome Typing and Viral Load Assays 
 
The ratio of viral genomic copy number to human genomic DNA was 
determined with bi-plex qPCR using EBV specific primers against BALF5 gene  
(Kimura et al. 1999) and human beta-actin gene. Primer sequences for BALF5;  
fw: 5`-CGGAAGCCCTCTGGACTTC-3`,  
rw: 5`-CCCTGTTTATCCGATGGAATG-3`,  
for b-actin;  
fw: 5`-TCACCCACACTGTGCCCATCTACGA-3`,  
rw: 5`-CAGCGGAACCGCTCATTGCCAATGG-3`  
 (Moormann et al. 2005).  
 
Genotyping the EBV DNA was performed using conventional primers 
spanning EBNA3C gene producing 153bp and 246bp products for type I and type II 
genomes, respectively. 
Primer sequences for EBNA3C; 
fw: 5`-AGAAGGGGAGCGTGTGTTG-3`,  
rw: 5`-GGCTCGTTTTTGACGTCGG-3`. 
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B. EBV Genome Sequencing Complete Protocol 
 
Input DNA preparation: 
 
1. Extraction/Isolation/Purification of DNA from clinical specimen (Biopsy, 
plasma, cell line) 
2. Quantification of Input DNA with PicoGreen 
3. Whole Genome Amplification with GenomiPhi v2 Phi29 polymerase 
4. Alternatively, PCR-sWGA 
5. Cleaning/purification after WGA using XP Ampure beads 
6. Quantify the Amplified DNA with PicoGreen 
7. Check the quality of DNA with NanoDrop for OD 260/280 ratio 
8. Determine viral/human DNA before and after WGA 
 
Sequencing Library Preparation: 
 
9. Shearing DNA with Covaris ultrasonicator 
10. Assess DNA quality 
11. Blunt-end repair  
12. Cleaning/purification/”Size selection” using XP Ampure beads 
13. 3'-end Adenylation of DNA fragments 
14. Cleaning/purification using XP Ampure beads – 1.8x 
15. Y-shaped linker ligation 
16. Cleaning/purification using XP Ampure beads – 1.8x 
17. Barcode incorporation with PCR using indexed primers 
18. Cleaning/purification using XP Ampure beads – 1.8x 
19. Quantify library using Illumina adapter primers with Sybr-green qPCR  
20. Determine viral/human DNA in the library 
 
EBV Hybrid Selection Enrichment: 
 
21. Pool the libraries by balancing based on EBV DNA fragment contents. 
22. Hybrid pull-down with RNA baits 
23. After-enrichment PCR 
24. Cleaning/purification using XP Ampure beads – 1.8x 
25. Assess DNA quality 
26. Sequence on the same flow cell. 
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Input DNA preparation 
 
Step 1. Extraction/Isolation/Purification of DNA from clinical specimen 
(Biopsy, plasma, cell line) 
 
 
Step 2. Quantification of Input DNA for Sequencing Library Preparation 
using PicoGreen 
 
 
Step 3. Whole Genome Amplification with preamp 
 
For the preamplification reaction, we used regular PCR primers tiling across 
the virus genome in two pools with 20 primer pairs. Most of the primer sequences 
and the reaction conditions were obtained from Kwok et al.  (Hin Kwok et al. 2012b) 
except additional primers that are unique to type 2 genomes. Following the 20 cycle 
preamplification LD-PCR polymerase, reaction solutions were mixed with phi29 
reaction buffer containing 1.5 U phi29 polymerase and EBV genome specific 3’-
protected oligos  (Leichty and Brisson 2014). Then, we incubated at 30C for 16h.  
For whole genome amplification with GenomiPhi v2 kit, please follow the kit 
guidelines. Preamp-sWGA is a method for pre-amplification template DNA boostup 
with tiling PCR primers followed by whole genome amplification using Phi29 and 
EBV specific protected oligos.  
This reaction condition has been tested for 100 EBV copies/20ng Template 
DNA. So, input DNA should have at least this level of viral copy as a starting 
material (Please adjust the H2O volume depending on template DNA vol). 
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Preamp PCR reactions with two pools; 
  
 
1x 25uL 
Reaction   
1x 25uL 
Reaction 
LongRange PCR Buffer 
with Mg2+, 10x 2.5  
LongRange PCR Buffer 
with Mg2+, 10x 2.5 
dNTP mix (10 mM of 
each) 1.25  dNTP mix (10 mM of each) 1.25 
Primer Pool 1 2  Primer Pool 2 2 
LongRange PCR Enzyme 
Mix 0.15  
LongRange PCR Enzyme 
Mix 0.15 
5x Q-Solution 5  5x Q-Solution 5 
MgCl2 (25mM) 0  MgCl2 (25mM) 0 
H2O 0  H2O 0 
Total 11  Total 11 
Template DNA 14  Template DNA 14 
 
 
20 cycle amplification: 
 
95C for 3min 
REPEAT 20 times 
Denature at 95C for 30sec 
Gradient Annealing 58C to 49C for 15sec each 
Extension at 72C 7min 
Final Extension at 68 for 10min 
4C hold 
 
Following the preamp reactions, mix the two reaction solutions well and proceed to 
next steps. Denature the mixture at 95C 3min, keep on ice immediately. 
  
Important: this denaturation allows sWGA oligos to anneal on ssDNA 
template at isothermal conditions. So, please do not skip denaturation 
step! 
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Post-PCR sWGA: 
 
Oligo sequence (5' to 3') used for preparing “EBV oligo mix” for the sWGA reaction: 
 
GCCGCOG 
CCGCCEC 
GGTCTOG 
GCGGGOC 
CGCCAOC 
CCGCCFC 
GTGGCOG 
GGGCCET 
CGGGGZC 
GTCCGEG 
 
Prepare the following mixture for every sample: 
 
For 50uL 
preamp mix: 
phi29 Reaction 
Buffer 10X 7 
dNTP (Mix-2)* 3 
EBV oligo mix 7 
phi29 Polymerase 
(10U/uL) 2 
BSA (0.1ug/uL) 100x 0.7 
H2O 0.3 
total 20 
 
*dNTP Mix-2 (GTP, CTP, ATP,TTP; with 30, 30, 5, 5 mM, respectively) 
 
When 20uL reaction solution is ready, directly add to denatured solution preamp 
mix. 
 
Incubate at 30C for 16h followed by 65C for 15min. 
 
 
 
  
199 
Step 4. Cleaning/purification after WGA using 1.8X XP Ampure beads elute 
in 70uL H2O 
 
Quantify the Amplified DNA with PicoGreen 
 
Check the quality of DNA with NanoDrop for OD 260/280 ratio 
 
Determine viral/human DNA before and after WGA qPCR 
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Sequencing Library Preparation 
 
 
Step 5. Shear DNA  
 
Make sure genomic DNA samples are of high quality with an OD 260/280 ratio 
ranging  
from 1.8 to 2.0.  
 
Covaris recommends: 
DNA input: from 100 ng to 5 μ g purified DNA  
Buffer: Tris EDTA, pH 8.0  
DNA quality: Genomic DNA (> 10 kb). For lower quality DNA, Covaris recommends 
setting up a time dose response experiment for determining appropriate treatment 
times. 
Sample volume: 130ul (+/-5ul) for microTUBE AFA Fiber Snap-cap (Covaris p/n 
520045) 
 
For each DNA sample to be sequenced, prepare 1 library.  
 
1. Dilute 3 μg of high-quality gDNA with 1X Low TE Buffer in a 1.5-mL LoBind 
tube to a total volume of 130 μL.  
 
2. Set up the Covaris E-series or S-series instrument.  
 a. Check that the water in the Covaris tank is filled with fresh deionized 
water to the appropriate fill line level according to the manufacturer’s 
recommendations for the particular instrument model and sample tube or plate in 
use.  
 b. Check that the water covers the visible glass part of the tube.  
 c. On the device control panel, push the Degas button. Degas the instrument 
for least 2 hours before use, or according to the manufacturer’s recommendations.  
 d. Set the chiller temperature to between 2°C to 5°C to ensure that the 
temperature reading in the water bath displays 5°C.  
 e. Optional. Supplement the circulated water chiller with ethylene glycol to 
20% volume to prevent freezing.  
 
Refer to the Covaris instrument user guide for more details.  
 
3. Put a Covaris microTube into the loading and unloading station.  
Keep the cap on the tube.  
 
4. Use a tapered pipette tip to slowly transfer the 130-μL DNA sample through the 
pre-split septa.  
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Be careful not to introduce a bubble into the bottom of the tube.  
 
5. Secure the microTube in the tube holder and shear the DNA with the settings in 
the table below, depending on the Covaris instrument SonoLab software version 
used.  
 
The target DNA fragment size is 300 to 500bp (peak at 400bp).  
 
 
Shear settings for Covaris instruments using SonoLab software prior to version 7: 
 
Instrument E220: 
Setting Value  
Duty Factor 10% 
Peak Incident 
Power (W) 
140 
Cycles per 
Burst  
200 
Time  55 
Temperature 4° to 7°C 
 
6. Put the Covaris microTube back into the loading and unloading station.  
 
7. While keeping the snap-cap on, insert a pipette tip through the pre-split septa, 
then slowly remove the sheared DNA.  
8. Transfer each 130-μL sheared DNA sample to a 96 well plate. 
 
!!! KEEP 65 ul of Sheared DNA as back up. 
 
 
”Size selection” using XP Ampure beads. 0.3X (20uL) discard beads. Add 
0.9X (60uL) more keep the beads. Elute DNA in 17uL H20. 
 
Assess quality with the 2100 Bioanalyzer DNA 1000 kit (optional) 
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Step 6. Blunt End Repair 
 
Quick Blunting Kit (NEB: E1201L) 
 
Mix the following components with Sheared and Purified DNA (up to 5 µg, 17 µl) in 
a sterile well of 96 well plate: 
 
Using Quick Blunting Kit 
(NEB: E1201L) 
μl Per 
reaction 
Sheared Clean DNA 17ul 
10X Blunting Buffer 2.5 
10mM dNTP Mix 2.5 
Blunt Enzyme Mix 1 
H2O 2 
Total 25 
 
Place the reaction into a thermal cycler and set the cycler for 20min at 12C followed 
by 15min at 37C. Immediately inactivate enzyme in the blunting reaction by 
heating at 70°C for 10 minutes. 
 Cycler:  
 20 min at 12°C  (Do Not heat the lid) 
 15 min at 37°C  (Do Not heat the lid) 
 10 min at 70°C 
 
 
Step 7. Cleaning/purification using 1.2X XP Ampure beads. Elution volume is 
~30uL. 
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Step 8. Adenylate the 3' end of the DNA fragments 
 
Klenow Fragment (3'-->5' exo-) (NEB: M0212S) 
dATP (NEB: N0440S) 
 
Mix the following components in a sterile well of 96 well plate: 
 
End repaired Clean DNA 30uL 
second strand buffer/10× 
NEB Buffer 2 5 
dATP (10 mM) 2 
Klenow Fragment 3' to 5' 
exo– (5 U/μl) M0212L 3 
H2O 10 
Total 50 
 
 
Incubate 60min at room temperature (25°C). Immediately inactivate enzyme in the 
adenylation reaction by heating at 75°C for 20 minutes. 
 Cycler:  
 60 min at 25°C (Do Not heat the lid) 
 20 min at 70°C 
 
 
Step 9. Cleaning/purification using XP Ampure beads – 1.8x. Elution 
volume is ~20uL. 
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Step 10. Y-shaped Adapter Ligation 
 
Add the Y-shaped adapters (oligonucleotide sequences © 2007–2011 Illumina, Inc. 
All rights reserved.). To prepare the Y-shaped adapter, mix 25 μl adapter 
oligo 1 and oligo 2 (each at 50 μM stock concentration). ONLY ONCE STEP! 
 
Heat at 95°C for 2 minutes, then ramp down slowly to room temperature. We 
usually heat the oligo mixture in an aluminum heat block for 2 minutes. Then 
remove the block from the heater and let it cool down to room temperature, for 
approximately 30 minutes.  
 
Using Quick Ligation™ Kit (M2200L) 
 
Quick Adapter Ligation: 
μl Per 
reaction 
A-tailed Clean DNA 20uL 
2X Quick Ligation Buffer 25 
Y shaped adapter (10 μM) 2 
dATP (100 mM) 1 
Quick Ligase 2 
Total 50 
 
Incubate at room temperature for 30 minutes.  
 
Step 11. Cleaning/purification using 0.9X XP Ampure beads. Elution 
volume is ~30uL. 
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Step 12. Barcode incorporation with PCR using indexed primers 
 
 
PCR amplify the Library: 
μl Per 
reaction 
Adapter ligated Clean DNA 30uL 
2X KAPA HiFi HotStart 
ReadyMix 25 
dNTP (10 mM each) 2 
10 μM PCR Primer 1 
(barcoded-optional) 1.5 
H2O 0 
Total 58.5 
10 μM PCR Primer 2 
(barcoded) 1.5 
 
 
Incubate the tube at 98°C for 40 seconds, 65°C for 30 seconds and 72°C for 30 
seconds. After the incubation, pause the PCR machine and then add 1.5 μl 10 μM 
PCR Primer 1. Continue the PCR with 10 cycles of 98°C for 10 seconds, 65°C for 30 
seconds, 72°C for 30 seconds, followed by incubation at 72°C for 3 minutes.  
 
 
Step 13. Cleaning/purification using 0.9X XP Ampure beads. Elution 
volume is ~30uL. 
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Step 14. Quantify library qPCR using Illumina adapter primers. 
 
 KAPA Library Quantification Kit Illumina® platforms - KK4824. Follow the 
protocol. 
 
Quantify Library: 
μl Per 
reaction 
2x Power SyberGreen PCR Mix 12.5 
qPCR Primer Mix (2 uM) P7-3, 
P5-2 2.5 
H2O 0 
Total 15 
 
 
Step 15. Determine viral/human DNA in the library with Sybr-green qPCR. 
Pool the libraries by balancing based on EBV DNA fragment contents. 
 
Step 16. Hybrid pull-down with RNA baits. >36h 
 Follow MyBait protocol !!! 
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Step 17. After-enrichment PCR  
 
qPCR Primer 1 - HPLC Purified - 5’AATGATACGGCGACCACCGA -3’  
qPCR Primer 2 - HPLC Purified - 5’CAAGCAGAAGACGGCATACGA -3’  
 
Post-Capture amplify the 
Library: 
μl Per 
reaction 
2X KAPA HiFi HotStart 
ReadyMix 25 
dNTP (10 mM each) 2 
 (10 μM each) PCR Primer 
Mix – P5-2/P7-3 1.5 
H2O 5.5 
Total 34 
 
Step 18. Cleaning/purification using XP Ampure beads – 1.8x 
 
Assess quality with the 2100 Bioanalyzer High Sensitivity DNA kit 
 
 
Step 19. EBV qPCR→ Pool to one tube. 
 
Step 20. Sequence on the same flow cell. 
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